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Dose-Response Relationships for
Carcinogens: A Review
by Lauren Zeise,* Richard WiIson,t and
Edmund A. C. Croucht
We review the experimental evidence for various shapes ofdose-response relationships for carcinogens
and summarize those experiments that give the most information on relatively low doses. A brief review
of some models is given to illustrate the shapes of dose-response curve expected from them. Our major
interest is in the use of dose-response relationships to estimate risks to humans at low doses, and so we
pay special attention to experimentally observed and theoretically expected nonlinearities. There are few
experimental examples ofnonlinear dose-response relations in humans, but this may simply be due to the
limitations in the data. The several examples in rodents, even though for high dose data, suggest that
nonlinearity is common. In some cases such nonlinearities may be rationalized on the basis of the phar-
macokinetics of the test compound or its metabolites.
Introduction
The primary reason for the authors' interest in dose-
response relationships for carcinogens is the need to
estimate human risks at low doses. Typically, the only
data available are the results of animal experiments at
high doses, perhaps augmented by scanty epidemiol-
ogical information (together with test results from a
battery of short-term tests, which are not considered
further here). Conclusive demonstration of the exis-
tence or nonexistence of certain aspects of dose-re-
sponse relationships for carcinogens would greatly ease
the task of risk assessment, in turn making regulation
ofcarcinogens, and the explanation of such regulation,
simpler. For example, if a threshold dose, below which
there is no response, exists, then exposure up to that
threshold would clearly pose no risk. Evidently, there
are many other reasons for study of dose-response re-
lationships at all doses, but in this review we concen-
trate onthelowestdosesthatgiveexperimentally meas-
urable response. In particular, we are interested in the
extent to which measurable dose-response curves for
cancers .deviate from linearity.
This review surveys the relevant human ("Human
Studies") and whole animal ("Animal Studies") experi-
mental data on carcinogenesis at relatively low doses,
with an outline oftheories that have been advanced and
remain consistent with this data ("Dose-Response For-
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mulae"). Of special interest are the observed nonlin-
earities in dose-response relationships, and the possible
explanations for them.
Most models ofthe cancerprocess are constructed by
describing (mathematically) a set ofelementary biolog-
ical processes which are supposed to be fundamental.
The effect of doses ofcarcinogens on these elementary
processes is generally assumed to be the simplest pos-
sible (e.g., described by a chemical reaction rate), but
the dose-response relationship for the whole model will
usually be as arbitrary as the assumptions made for
these elementary processes. Many ofthe mathematical
models suggested are expressions ofthe biological idea
of a multistage process. We demonstrate how many
differentdose-responseformulae canbeobtained within
this one framework, although such formulae might also
arise from alternative theoretical frameworks. Conse-
quently, to avoid confusion, it seems preferable to refer
to currently used dose-response relationships by some
descriptor of the mathematical formulae, rather than
by a descriptor of the particular theory or model used
to justify them.
"Human Studies" and "Animal Studies" summarize
those experimental observations on cancer induction
which show most clearly the shapes of dose-response
curves. Epidemiological studies and bioassays can use
too few subjects to give direct information about doses
atwhich excesstumorratesarebelowabout 1%. Where
large numbers ofpeople or animals have been exposed
to various levels of a carcinogen we obtain the closest
approach to low doses. In addition, studying the out-
comes of a large number ofsmall experiments can giveZEISE, WILSON, AND CROUCH
some statistical information about shapes of dose-re-
sponse curves.
In "Human Studies" we discuss the small amount of
dataondose-response relationships inhumans. Thebest
sets of data are those on cigarette smoking in British
physicians, with asublineardose-response relationship.
In addition are the results of a study oflung cancer in
those occupationally exposed to coke oven emissions
(which contain many constituents present in cigarette
smoke). Exposure toradiation is known toproduce sev-
eral human cancers, and there are sufficient data to
estimate dose-response curves. The effects can vary
substantially, depending on the route of exposure, ra-
diation quality (high versus lowlinearenergytransfer),
and target site, leading to highly varied dose-response
relationships. Various factors modulate the human re-
sponse to carcinogens, leading to complications in dose-
response relationships. This is illustrated by the case
of aflatoxin B1, where human response appears to be
explicable only if various other characteristics of ex-
posed populations are also taken into account.
In "Animal Studies" we discuss animal data. Even
though there are many more data than in the human
case, they have been gathered in the course of exper-
iments on many more materials, so that there are few
detailed dose-response relationships. It is possible to
analyze a number of small experiments to determine
the dose-response relationships that are consistent with
the whole set of data, although this requires assump-
tions about comparability which may be difficult tojus-
tify. Alternatively, analysis of many experiments with
substantially the same experimental design may give
some insight into the shape of dose-response curves in
general. There have been two reported experiments
using thousands ofanimals exposed to single chemicals:
one in which mice were exposed to 2-acetylaminofluor-
ene, and one in which rats were exposed either to die-
thyl- or dimethyl-nitrosamine. Each shows two distinct
types of dose-response relationships corresponding to
two different tumor sites. Inaddition, moderately large
experiments have been performed on saccharin, vinyl
chloride, and radiation. All show nonlinear dose-re-
sponse relationships, the shape of which may be ex-
plained by various biological mechanisms.
We conclude with a discussion oftheproblems ofreg-
ulating carcinogens. Although it is clear that nonlinear
dose-response relationships are experimentally preva-
lent and that biologically based theoretical reasoning
leads to such nonlinearities, it israrely possible to iden-
tify when and to what extent they will occur in humans.
To remain conservative, it is still necessary to assume
that dose-response curves may be linear at sufficiently
low doses (although even this may fail to be always
conservative). However, in analyses that attempt to
obtainabestestimate ofrisk(ratherthanaconservative
one), orperhaps forthe legal purpose ofassigning caus-
ation in a particular case in which there is substantial
experimental evidence, a nonlinear extrapolation may
be more appropriate.
Dose-Response Formulae
Introduction
In this review we wish to distinguish three concepts
that are often confused. The first is the abstract de-
scription of biological processes, the second a mathe-
matical model for that process, and the third any for-
mulaethat canbeused to summarizecertainpredictions
of the mathematical model. In the literature on dose-
response relationships, it is often unclear which (ifany)
of these concepts is intended, since any or all of them
may be referred to as a "model."
Knowledge about the processes involved in the ulti-
mate production of cancers has advanced substantially
in the recent past. It is clearthat acomplete description
willrequire knowledge ofmany processes, includingthe
transport and metabolism of materials throughout the
body, damage and repair of DNA and other cellular
components, and stimulation and inhibition of cell
growth. Such a complete description should, for ex-
ample, be able to explain the phenomena ofbackground
response, promotion, and differences between individ-
ual animals. With such a complete description, which
lies some distance in the future, it should be possible
topredict howtheprobabilityofcancervaries withdose
of carcinogen (i.e., a dose-response relationship). Fig-
ure 1 is one simplified description (1,2) ofthe processes
leading to liver cancers. We display it not to endorse
its correctness, but to illustrate the complexity to be
expected in such descriptions, and the many places at
which a xenobiotic might exert influence; the ultimate
dose-response relationship for that xenobiotic may be
theresultofinteractions at any one oralloftheseplaces.
For any abstract description of a biological process,
it is possible to write down mathematical models that
incorporate in a parametric way all the known infor-
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FIGURE 1. One biological description ofliver carcinogenesis (1,2).
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mation about the process. Such models may differ in
formalism (but be mathematically equivalent), or may
differin contentifdifferent assumptions aremadeabout
any unknown details of the process. Since the known
information comes from experiments, which are nec-
essarily subject to some error, it should not be sur-
prising that different mathematical models can be con-
structed which nevertheless agree in all details with
known information. Furthermore, it is possible that the
same mathematical model can be used to describe dif-
ferent biological processes, although the parameters of
the model would have a different meaning. Recent at-
tempts at developing mathematical models to (among
other things) predict dose-response relationships have
usually focused on describing in detail one part (or a
few parts) of the processes leading to cancer, but the
limitations of available data are so great, and the bio-
logical processes are so complex, that these attempts
have necessarily been incomplete.
Fromthe mathematicalmodel, itisgenerallypossible
to extract some formulae that summarize the predic-
tions ofthe model in simplified situations. This may be
the only use for the mathematical model, since the pa-
rameters which are used in its construction may not be
directlymeasurable. Insuchacase, theonlyinformation
the mathematical model provides is the expected func-
tional relationship between various parameters of the
model. Specifically, for our purposes, the model would
provide information about the relationship between the
dose of some material and a probability of cancer. It is
important to realize that while any specific model may
predict a particular shape for a dose-response relation-
ship, the converse is not true. The same formula for a
dose-response relationship can be produced by many
different mathematical models (and similarly, by many
different biological descriptions). To refer to the use of
a particular formula for a dose-response relationship as
being the use of a particular model is therefore incor-
rect, and we try to avoid such usage in this review.
Dose-response models are formulated either to aid in
the development and verification of biological theories
of carcinogenesis, or as a means of determining safe
levels of exposure to carcinogens, and reviews of the
literature emphasize either one aspect or the other. In
this review we emphasize the second aspect. Several
authors have reviewed the models and the correspond-
ing dose-response formulae most commonly used for
estimating human risks from animal bioassay data (3-
9). Whittemore (10) and Whittemore and Keller (11)
give excellent reviews ofquantitative models ofcarcin-
ogenesis based on a multistage description, presenting
their historical development and recent formulations.
The recent review of detailed multistage models by
Forbes and Gibberd (12), who concentrate on age ef-
fects, provides a useful update to their work. A guide
to the literature on dose-response models is given by
Krewski and Brown (13) and the National Cancer In-
stitute (14).
The dose-response modelsused togaininsight on car-
cinogenesis are more complicated and require much
more data than those presently used by government
agencies in setting acceptable human exposures to car-
cinogens. Yetitisnowrealizedthatcertainassumptions
made in determiningthe safety ofone chemical may not
apply to another, so that it may now be more appro-
priate to choose the dose-response formulae used for
standard setting on the basis of models which incor-
porate more information on biological processes.
Although a simple and precise definition of a carcin-
ogenis straightforward, e.g., "anagentwhich cancause
cancer in the species under consideration," further ex-
amination reveals that different types of carcinogens
can be usefully distinguished. Distinctions have been
drawn between initiators, promoters, cocarcinogens,
true carcinogens, primary carcinogens, direct carcino-
gens, indirect carcinogens, secondary carcinogens,
early carcinogens, late carcinogens, and complete car-
cinogens by one or more authors. These distinctions
generally rely on a description or model of carcinogen-
esis which may or may not have wide acceptance. We
discuss the meaning of some of these distinctions later
in this section.
Some Constraints on Dose-Response
Formulae
When choosing a dose-response formula in order to
fit experimentally observed data (on cancer incidence)
and toextrapolate to lowdoses, itisnecessarytoensure
that the formula is indeed that obtained from a math-
ematical model ofthe cancer process. This is not a very
strong constraint, since many such models have been
proposed, but it does have some consequences. In par-
ticular, a background rate of tumors (spontaneous in-
cidence) and the variation oftumor incidence rate with
age and time must be consistently incorporated.
Mathematical Model from Biological Description.
Consider again the biological description of liver car-
cinogenesis developed by Farber (1,2), shown sche-
matically in Figure 1. In this description, the first evi-
dencethatasteptowardthedevelopmentoflivercancer
has occurred is the appearance of nodules of hepato-
cytes, visible to the naked eye (>2 mm diameter).
These nodules arepresumed to come frominitiated cells
(those in which DNA has been modified, possibly by
interaction with a xenobiotic or its metabolite). In ad-
dition to DNA modification, a cycle ofcell proliferation
is required. (This proliferation requirement may be the
major mechanism of action for those liver carcinogens
thatarecytotoxictolivercells, see"TrueandSecondary
Carcinogens.") The initiated cells are supposed to have
acquired resistance to the inhibition ofcell proliferation
exhibited by normal cells. Observable nodules develop
rapidly from these resistant hepatocytes (within days
of initiation). An assay for the induction of resistant
hepatocytes and their subsequent growth into nodules
was developed by Farber and colleagues. He notes that
although after 5 to 6 weeks from the time of initiation
the liver may contain as many as 1,000 nodules, 8 to 10
weeks after this, over 90% have disappeared, having
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redifferentiated back into normal-appearing liver tis-
sue. The occurrence ofsome unspecified but rare event
causes new hepatocytes to be formed within the per-
sistent nodules. These new hepatocytes also grow, and
thus lead to nodules within nodules, which are the sites
of liver cancer.
All of these processes can be described using the
mathematical models discussed here (and using other
models) to generate a model ofthe whole process. For
example, one might wish to describe the activated liver
by the amount of DNA modified. The interaction of a
xenobiotic with DNA might be described by a one-hit
model to quantitatively predict the number of DNA
adducts and thus the total amount of DNA modified.
However, obtaining accurate models for some of the
subprocesses involved will not necessarily ensure an
adequate model forthe whole process. Thus, evenifthe
one-hit model holds for DNA adduct formation within
the cell, the dose-response relationship for the whole
animal could still be highly nonlinear if, for example,
repair is dose-dependent, or if nonlinear pharmacoki-
netics are involved in metabolite formation, or if two
dose-related mutations arerequiredratherthanthe sin-
gle one implied by the use of a one-hit model.
The usual hope in using a dose-response formula
based on amathematical modelisthatthewholeprocess
is dominated by the part that is modeled. Other pro-
cesses are known to occurand are not incorporated into
the model, but these processes are supposed to have a
secondary effect.
Backgrounds (Spontaneous Tumors). It is ob-
served that in any whole animal experiment on a par-
ticular xenobiotic, the control animals may also develop
tumors. Such spontaneous tumors may be due to other
carcinogens than the one ofinterest, or may arise as a
necessary consequence of some normal process and so
be truly spontaneous. Infitting dose-response formulae
it is necessary to account for such a background tumor
incidence. The mathematical problems and the impli-
cations for the processes being modeled have been ex-
tensively treated (3,15-17), and we summarize some
major points.
There are many ways of incorporating spontaneous
tumor incidence, but they can usually be modeled as an
admixture oftwo particular cases:
1. An independence assumption: The cancers pro-
duced by the xenobiotic are completely independent of
background tumors. The total probability of a tumor,
p(d), assuming a background rate a, is then
p(d) = ca+ (1-ca) * F(d).
this independence between background and dose-de-
pendent tumors is a correct description, then any non-
linear dose-response function for F(d) will result in a
nonlinear relation between the total probability of tu-
mor and dose.
2. An additive assumption: The spontaneous cancers
are produced by the same mechanisms as the cancers
produced bythexenobiotic. Inthis casethebackground
tumors may be considered to be produced by an effec-
tive background dose dB, and the total probability of
tumor with an external dose d is then:
p(d) = F(d+dB) # F(dB) + d *
o9F dB cld
= o + P9 . d (3)
This always gives a response linear in the external
dose at sufficiently low doses ifthe first derivative ofF
isfinite. (Notethatthe Heaviside functioninthethresh-
old model is not continuous, see "Threshold Formulae,"
and its derivative is not finite at the position of the
threshold.) Figure 2 illustrates this extreme case. In
practice, the constant of proportionality (1') may be
small, so that this linear region of the dose-response
functionisnotexperimentally observable. Theideathat
the carcinogen may add to an effective background dose
has been often used to support the claim that a linear
dose-response formula is never overly conservative.
Between these extremes are many intermediate pos-
sibilities. One isthat only cancers arisingfromthe same
cell type are similar for the purposes considered here.
For very rare cancers, the effective background dose
dB may be practically zero and the shape of the dose-
Differential Linearity
Incremental
Response
(1)
where F(d) is the probability of a tumor solely due to
the externally applied dose d. Forexample, forthe one-
hit model this gives
p(d) =cx+(l-a)(1-e- a )
=1 - (1 - a)e-0d (2)
This procedure is, in essence, that ofAbbott (18). If
Zero
Background
FIGURE 2. Small increments in dose above abackground give small,
linearly related increments in response, even for nonlinear dose-
response functions.
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response curve indistinguishable fromthatexpectedun-
der the assumption ofdose independence. On the other
hand, if the cancer in question is common, with dB rel-
atively large, the response at low doses ofthe external
agentwouldbelinear. KrewskiandVanRyzin(3)tested
the effect of the additive assumption by incorporating
it into three dose-response formulae (extreme value,
logit, and probit). Applying these formulae to a series
ofdata sets, effective background doses were estimated
and extrapolations down to an excess risk of 10-0 were
performed. When the observed background tumor in-
cidence was greater than about 1%, the predicted re-
sponse at low dose was essentially linear in dose. How-
ever, for background tumor incidence less than 1%, low
dose linearity did not result when the dose-response
formula allowed for curvature, and the high dose data
exhibited nonlinearity. As a precautionary note, the
particular human cancer or cancers that any particular
carcinogen might cause are generally unknown, and it
may be necessary to assume that it will cause a common
cancer ifextrapolation ofanimal results to humans is to
be performed.
Time andAge. Most uses of dose-response formu-
lae, in particular for estimatingrisks at low doses, have
ignored the age and time dependence of cancer inci-
dence. This is sometimes adequate if the experimental
data under analysis are for subjects exposed continu-
ously for a fixed time to a fixed level of carcinogen and
if the age distributions of subjects in the various dose
groups, includingthecontrols, donotdiffer. Often, how-
ever, this is not the case.
AGE CORRECTIONS. First, inestimatingrisks, there
is the problem of competing risks. Smokers die before
theirtime notonly oflungcancer; they are alsofarmore
likely than nonsmokers to die ofheart disease, and con-
sequently there are fewer old smokers. Similarly, in
other epidemiological studies, those in the most highly
exposed groups are often the oldest; such is the case
withunderground minerswho are exposedtoradongas,
alungcarcinogen (see "Lung Cancer from RadonGas").
In bioassays, treated animals suffer reduced survival
due to chronic toxic effects, as well as cancer, so their
survival curves can differ substantially from control an-
imals. Discrepancies in longevity among dose groups
can lead to a spurious change in the shape of dose-
response curves, so some adjustment is needed. Non-
parametric techniques that do not require the assump-
tion of any specific dose and age response function are
frequently applied. Thetechniques ofKaplan and Meier
(19) canbeused toestimate the probabilitythat animals
in a treatment group would have had a specific cancer
ifthat group had the same age-specific noncancer mor-
tality as the untreated animals. There are some tech-
nical disadvantages with this approach, and so Peto and
colleagues have proposed an alternative nonparametric
approach (20). In each treatment group, the observed
number ofpeople or experimental animals with tumors
is compared with the number expected if the exposed
groups had the age-specific tumor rates of all groups
combined. The ratio of observed-to-expected number
obtained using this procedure is approximately propor-
tional to the response curve required, allowing any cur-
vature of this dose-response relationship to be ob-
served, although there may be a bias toward flattening
of the curve at high doses. This technique was used to
analyzethedoseresponsecurvatureofthelargediethyl-
and dimethyl-nitrosamine experiment (see "N-diethyl-
and N-dimethyl-nitrosamines"). In estimating carcino-
genic potency it is sometimes more useful to apply a
parametric technique, i.e., to specify a dose-age-re-
sponse model and then to estimate the parameters of
this model from the observed data. A mixed technique
has also been used (21), in which the dose dependence
oftumorincidence was specified parametrically, butthe
age dependence was estimated nonparametrically. This
was the approach used to compile a consistent set car-
cinogenic potencies from an exhaustive review of the
literature (22,23).
VARIED DOSING SCHEDULE. A second problem in
estimating risks is that the exposure often is not con-
stant. Thisisalwaysthecaseforoccupational exposures
and frequently occurs in animal bioassays. Misleading
dose-response relationships can be obtained when the
age variation of the dose rate is ignored and modeling
is done using either estimates of cumulative exposure,
that is, total exposure throughout an individual's life-
time, or the average exposure rate (cumulative dose
divided by lifetime). A model that takes into account
both age and dose dependencies is needed to determine
a more realistic dose-response relation. The formulae
that result from such models can be divided into two
classes: in the first, I(d,t), the incidence at age t and
dose d, also called the hazard function, can be separated
into a product of an age-independent function of dose
[e.g., g(d)] and a dose independent function ofage [e.g.,
f(t)], so that I(d,t) = g(d) .f(t); in the second, this de-
composition ofthe hazard function is notpossible. Spur-
ious dose-response relationships can be obtained when,
for example, the dose rate varies, and a separable form
(usingonly cumulative dose) is used to analyzethe data.
Many dose-response formulae that include a specifica-
tion of dose and age dependence can be derived from
somespecialization ofmultistage models, and arebriefly
discussed in "Multistage Models."
Particular Models and Formulae
The Linear and Linear Exponential Formulae.
Perhaps the simplest dose-response relationship used is
that based originally on the one-hit description and cor-
responding model of radiation carcinogenesis formu-
lated by Crowther (24). The biological idea is that a cell
is damaged by arandom hit (inthe originalformulation,
from radiation; by extension, possibly from a chemical
molecule) and that it then grows inevitably to form a
cancer. A mathematical expression ofthis idea leads to
the formula,
Excess number of cancers in a population =
K Exposure
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It is necessary to allow for the fact that organisms
only die once, so that the probability ofgetting cancer
[p(d)] when exposed to a cumulative exposure or dose
d becomes
p(d) = 1 -exp(-fPd) -* * d for small d
(4)
The biological one-hit modelthatleads tothisformula
may be disputed even for radiation carcinogenesis. The
charged particle background due to cosmic rays is, at
the earth's surface, 104/min-m2-ster, or about 103/min
over the human body. Each of these charged particles
causes ionization as it passes through tissue. Even if
sensitive cells occupy only 1/1,000 ofthe body, this still
means that cosmic rays alone would initiate 1 cancer/10
min, or 105 in a lifetime-a factor 106 higher than the
observed cancer background rate. Tobringthe descrip-
tion into agreement with observation, one must pos-
tulate eitherthatthecellsmustsufferionizationdamage
in a very specific way, or that there are repair mech-
anisms. More recent knowledge of carcinogenesis sug-
gests that there is more than one stage in the progres-
sion to a cancer, so that a one-hit model cannot be
anythingbut anoversimplification. However, ifthefrac-
tion ofcells that arerepaired isindependent ofthe dose,
and if the target site of attack is independent of dose,
and if ionization at only one specific target site is re-
quired, the one-hit model might be an adequate de-
scription.
Nevertheless, the linear formula
p(d) = fld, (5)
and its modification for high doses
p(d) = 1 - exp(-B * d) (6)
and the equivalent formula modified to include a back-
ground cancer rate
p(d) =1 - (1- a)exp
or 1 - exp[-(a + b * d)] (7)
are often used to analyze data. The modifications for
high doses are for the probability ofdying ofcancer or
the probability that any individual animal has at least
one tumor. One can still postulate strict linearity
[N(d) = ,B d] between the total number of tumors and
the dose at high doses: one animal can have several
tumors, butthe animaliscountedonlyonce. Postulating
a one-hit model thus has implications for another ob-
servable measure, the number oftumors per animal, as
well as implying the formulae given for the probability
of a tumor.
However, asdiscussedpreviously, usingtheformulae
displayed does not imply the postulation of a one-hit
model. As discussed below, the same formulae can be
derived from, for example, various specializations of
multistage models. Furthermore, the use of these for-
mulaefordataanalysisalsogivesupperboundestimates
of risk for a wide variety ofmodels. We will therefore
refer to these dose-response formulae as "linear" (or
"proportional") (Eq. 5) or "exponential linear" (Eqs. 6
and 7), although we are not particularly careful in dis-
tinguishing these two, since they are equivalent at low
enough doses.
Because of the simplicity and importance of these
formulae, others are often compared to them. A subli-
near dose-response formula is one in which the curve,
fixed to be equal to the proportional (or exponential
linear) formula at each end, lies always below the pro-
portional curve; a superlinear formula is one in which
the curve, also fixed to the proportional (or exponential
linear) one at each end, lies above the proportional
curve. Examples of super- and sublinear curves are
given in Figures 5 and 6, respectively. Such curves will
also be described as cases of downward curvature and
upward curvature, respectively, to indicate the shape
of the curve as the dose (on the x-axis) is increased.
ThresholdFormulae. It is generally accepted that
organisms have a certain tolerance for poisons; exceed-
ing some threshold dose will result in overt effects. An
extreme form of such a threshold dose-response rela-
tionship can be expressed as
p(d) =H(d-dT) (8)
where H is the Heaviside unit function, and dT is the
threshold dose (Fig. 3). Above the threshold aresponse
is certainly exhibited; below the threshold no response
is exhibited. More generally, a threshold-type dose-re-
sponse relationship has some particular dose dT, the
threshold dose, below which the response of interest
may be considered negligible, and above which the re-
sponse grows rapidly.
Schaeffer (25) has argued that the dose-response re-
lationship for chemical carcinogens must include a
threshold because carcinogenesis involves chemical re-
actions, which are subject to free energy and entropy
constraints. The "reactions will exhibit the usual mass
requirements of more common chemical reactions: the
single molecule causing cancer theory is chemically and
biologically unrealistic." These ideas were incorporated
into a threshold model, the "filter model" (4), derived
from thermodynamic ideas to describe tumor response
in whole animals, and the resulting dose-response for-
mulae were used to analyze animal data at high doses.
p(d) 1.oh
dT Dose,d
FIGURE 3. The prototype threshold dose-response function.
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However, it seems unlikely that such thermodynamic
thresholds are high enough to be of any consequence,
even at very low doses, as can be seen from the obser-
vations on DNA carcinogen adducts.
It is now possible to measure the concentration of
such adducts at very low levels (26). Extraordinarily
small concentrations of adducts have been associated
with very small exposures to carcinogens. The relation-
ship between exposure and adduct concentrations fortwo
potent carcinogens, aflatoxin andbenzo[a]pyrene, appears
to be linear, indicating the potential for nonthreshold bi-
ological activity at very low doses.
The Probit Formula. GENERAL. There are cer-
tainly variations inindividualtolerances topoisons. The
probit model (27), used to estimate the LD50 (the acute
dose at which 50% mortality occurs within a short time
in a test population) from mortality data on animals,
may be derived by assuming that a threshold dose (dT)
exists for each individual, but that this threshold dose
differs for different individuals in the population. Ifthe
individual threshold doses are lognormally distributed
with a logarithmic mean pt = log(LD50) and logarithmic
standard deviation a, then the expected fraction [p(d)]
of animals dying at some dose d is given by
0.6
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FIGURE 4. A probit dose-response function (Eq. 11 with a = 0 and
c = 0). Inset is the same function at much lower doses, showing
curve rapidly becomes sublinear at low doses.
exp ( )2
2 d
which can be rewritten as
1 la+b-log d {1 2 dy
p(d) =9= Jb lo
=(a+b.logd)
(9)
(10)
where '~(D) is the Standard Normal Integral (Fig. 4).
When this formula is graphed as a function of dose
(d), it is seen to have an effective threshold, since the
expected fraction of animals affected rapidly becomes
negligible (faster than any power of dose) as the dose
is decreased. It has enjoyed great success in, and is the
standard for, the analysis of acute toxic effects. It con-
tains two constants, and thus may be expected to fit
small data setsbetterthan oneparameterformulae (like
the proportional or threshold formula), but for such
acuteeffectsitwouldbedifficulttofind abetterformula.
(In all cases, inclusion of a background response re-
quires at least one more constant, but for modeling
acute mortality the background is effectively zero.)
THE MANTEL-BRYAN PROCEDURE. The probit
model was derived for use on noncarcinogenic re-
sponses, but Mantel and Bryan (28) suggested its use
formodeling response tocarcinogensinordertoprovide
a method of setting a safe exposure. Their suggestion
was generally accepted, and until recently, a procedure
based ontheprobitmodel, the"ImprovedMantel-Bryan
Procedure" (29), hasbeenwidelyused (e.g., bytheFDA
until 1977).
For conservatism, the slope parameter (b in Eq. 10)
was assumed to be unity when base 10 logarithms were
used, so that every 10-fold decrease in dose corre-
sponded to a unit decrease in normal deviate. This
choice was made from experience with experimental
data and reduced the number offree parameters in the
formula. However, to account for spontaneous tumors,
Mantel et al. introduced an additional parameter, "c,"
the expected (spontaneous) incidence in untreated an-
imals. This they assumed to be independent of the in-
cidence induced by the carcinogen, and so Abbott's cor-
rection is employed. The resulting formula for
probability of cancer as a function of dose is
p(d) = c+ (1
- c) .4(a+log1od) (11)
It was suggested that maximum likelihood proce-
dures be used to determine a, c, and their confidence
bounds from experimental data, and also that high dose
groups be progressively eliminated to obtain the lowest
ofthe upper confidence limits on a, call it a*. The safe
level, d*, correspondingto apredetermined deminimis
excess risk, say r*, is then given by solving
r* = 4P(a* + log1o d*) (12)
using the estimated value of a*.
The GammaMultihitModel and WeibullFormula.
The gamma multihit model may be derived as a gen-
eralization ofthe one-hit model. Instead ofjust requir-
ing asinglehit on acell, itispostulatedthat somecritical
number, k, of hits are required before a cell becomes
cancerous. Rai and Van Ryzin (30) derive a dose-re-
sponse formulaby assumingthatthe probability for any
single hit is proportional to dose, and the probability
1 (logd
p(d)
--
v aJ-7 1 0
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foragivennumberofhitsfollows aPoissondistribution.
Ifeach ofk hits required is indistinguishable, and ifall
are equally likely, then the probability for at least k
hits is given by
00
p(d) = (Ad) exp(-Ad)/i!
i=k
(13)
0t .3
0
02
4
C-
R .1 which can also be written as
AId Uk-le-u
p(d) = r(k) k>O (14)
where r(k) denotesthegammafunction. The parameter
X is the proportionality constant between probability of
any hit and dose. Although this formulawas derived for
an integral number k of hits, it can be unambiguously
extended to nonintegral values using the integral for-
mulation (Eq. 14), although the relation to the original
description is now unclear. For this dose-response for-
mula, the probability ofcancer, p(d), is proportional to
dk at low doses.
The gamma multihit formula is mathematically at-
tractive for simple data fitting (without assigning phys-
ical or biological meaning to the parameters) because it
has the two parameters A and k which are continuously
variable. It can be fit to data exhibiting strong super-
linearity (Fig. 5) or strong sublinearity (Fig. 6) very
well. However, the formula must be used with caution.
Ifthe best fit is k < 1, the predicted low dose response
will be much larger than that predicted by most other
formulae, since the derivative dp/dd is then infinite at
zero dose. Figure 5 is an example where the experi-
mental outcomes (liverangiosarcomas inrats, produced
by vinyl chloride inhalation) can be analyzed with a
gamma multihit formula to produce practically mean-
ingless predictions for low doses. The best fit is with
k 1/2(8). This seemsimpossible tointerpret in terms of
any biological description because half a hit makes no
a-
a .24
0
I-
0 .16;
5
cO .08
0
a.
1000 2000 3000 4000 5000 6000
DOSE (ppm)
FIGURE 5. A gammamultihitformula fitted (8) toexperimentaldata
(liver angiosarcoma caused by vinyl chloride) showingsuperlinear
behavior.
p(d) c dose28
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FIGURE 6. Agammamultihit formulafitted (8)toexperimentaldata
(bladder tumors caused by NTA) showing sublinear behavoir.
sense. Fitstosublineardose-responsedatacanalsogive
peculiar results. For example, for a cancer bioassay on
NTA (Fig. 6), which perhaps acts as a promoter, the
best estimate for k using a gamma multihit formula is
28, implying 28 hits-surely an overestimate.
A similar effect can occur when a Weibull formula is
used to analyze data. The Weibull formula is simply
p(d) = 1 - exp(-dk) (15)
and so corresponds to continuing the low-dose behavior
ofthegammamultihitformulatohigherdoses (although
this is not the only way it may be obtained). Cothern
et al. (31), in discussing trichloroethylene in drinking
water, attempttoconservatively estimate lowdoserisk
by using a Weibull formula, but in this case obtain
p(d) a /d- at low doses. While this procedure may give
a conservative estimate, the values obtained will have
little relation to actual risks. Only by using further bi-
ological information or using more data can sensible
conclusions be drawn about risks at low doses.
Multistage Models. HISTORICAL DEVELOPMENT.
The evolution of multistage descriptions for carcino-
genesis and the corresponding mathematical models
have been described in extensive reviews by Whitte-
more (10) and Whittemore and Keller (11). Table 1 out-
lines some of the history, beginning with the single-
stage model ofIverson and Arley (32), which describes
the transformation of a single normal cell to one that
divides into proliferating daughter cells. Even this
model can be traced even earlier to the one-hit model
of Crowther (24). Once the colony of abnormal cells
reaches a certain size, it is recognized as a tumor. This
theory could not adequately explain why the incidence
of human cancers generally increase with the fifth or
sixth power of age, so two extensions were proposed.
According to the first, by Fisher and Holloman (33),
tumors only develop ifanumberofcells (- 6) havebeen
independently transformed. Muller (34) and Nordling
(35) offered an alternative biologicaltheory, laterquan-
titatively expressed by Stocks (36) and Armitage and
z
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Table 1. Historical development of quantitative theories of
carcinogenesis.a they give incidence at age t, I(t), for a seven-stage pro-
cess as
A. Crowther (24): One-hit model ofradiation carcinogenesis
-p(d) = 1 - exp(b * d)
B. Iverson and Arley (32): Single stage theory; single cell theory
-a single transition from normal cell to transformed cell with
transition rate X(t)
-detectable tumor is a mass ofno cells which are descendants
of a transformed cell
-growth of cell mass follows a pure birth process with
birthrate 3
-I(t) = NfX(r)exp{ -f X(s)ds}1 (no - 1)e (t- (l
e-t- "))n-2dT, (X(r) = a + b d(T)
C. Fisher and Holloman (33): Multicell theory
-six or seven different transformed cells needed for tumor
development
-time from tumor detection to death negligible so that
mortality from cancer is the same as the rate of appearance
of tumors
-exposure ofcarcinogen from birth to death a constant at
dose d
-tissue with N cells
- (t) N* (NX)rtrl-(r - 1)! for Xt << 1, N >> r
-I(t) - N* (Nbd)rtr-ll(r - 1)! for X = bd
D. Stocks (36); Nordling (35); and Muller (34): Early multistage
theory
-single cell origin oftumor
-only one mutation experienced by a cell in one year
-transition rates the same for all stages, leading to I(t) X d'
E. Mixed multistage/multicell theory
-e.g., two kinds oftransformation required: type 1 and type 2
-for tumor to develop, r cells must have transformation 1;
n - r cells must have transformation 2
-I(t) - Nr(aj + bid)r(a2 + b2d)rn-/(n - r)!n!
F. Armitage and Doll (37): The basic multistage framework
-tumor develops from a single cell which has undergone a
number (say, r) different transformations
-transition rates not necessarily the same for all stages
-order oftransitions could be important
-simplified expression: For continuous exposure d, Xj = ai +
bid, with ai > 0 and bi
- 0.
I(t) - N * tr-l/(r - 1)! * Jj[(ai + bid).
i=l
-for 2 stages affected by the carcinogen, I(t)
_ Ntr-' (al +
a2d + a3d2)I(r - 1)!
aI(t) is the incidence rate; N, the number of cells in the tissue in
question; X, theprobabilityperunittime ofatransition; r, thenumber
ofstages required fortumordevelopment; and, d, thedose rate. Most
ofthe information taken from Whittemore and Keller (11).
Doll (37): cancer originates with a single cell that has
undergoneanumberofchanges. Stocks'formulationhas
each of the required changes affected by the presence
of a carcinogen to the same degree. However, experi-
mental evidence shows the incidence ofseveral cancers
to be proportional to the dose or the dose squared, but
not to higher powers ofthe dose, so Armitage and Doll
allow for different transition rates Xi between the re-
quired stages andalsoforthepossibilitythatsometran-
sitions are not affected by the presence of the carcin-
ogen. Thus, when mutations (or some other transition
event)arerareandthetransitionratesremainconstant,
I(t) = kAjA2A3A4AA\A7t6, (16)
where k is a constant. With these assumptions, tumor
incidence is directly proportional to the concentration
of the carcinogen if the probability of one mutation is
proportional to the carcinogen concentration and dif-
ferent factors are required for the other transitions. In
general, if a cell has to pass through r stages before
becoming overtly tumorous, then the probability per
unit time per cell for the transition to a tumorous state
is (providing I is small enough)
r
h(t) = IIJJij tr-l/(r - 1)! I..=iJ (17)
and the probability that any given cell is tumorous by
age t is just the integral ofthis:
It
Pr (t) = Ir(s)ds. (18)
If, as Stocks suggested, the probability of occurrence
ofeach mutation isproportionalto dose, then each term
Xi would be proportional to dose and the overall prob-
ability pr(t) would have a component proportional to
(dose)r.
For atotal ofNcells in an organ, the probability that
khavetransformedtoatumorous stateisjust(provided
that tumorous cells act independently)
pk(t)= (k) [NPr(t)] [1- Npr(t)]Nk
[Npr.(t)Jk
k! exp[-NPr(t)J (19)
where the Poisson approximation is effectively perfect,
since N is very large. Thus the probability of one or
more tumorous cells in the organ at age t is just
p(t) = 1 -exp[-Np,(t)]. (20)
If all but one ofthe Xs remain constant in time, and
one, say XA, varies when atotal ofrstages arerequired,
the incidence I can be obtained as
1(t) = 1 (8- 1)!(r-S)!
Ai)
i=l,i$
f Ax$-'(t -x)'-Jdx
(21)
This expression can be useful in analyzing data from
experiments with discontinuous dosing (38-40).
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For example, if the carcinogen only affects the Sth
stage, and the effect on this stage is linear in some
effective dose rate [d(t)], which may vary with time,
combining the last two equations gives
p(d,t) =1-exp{- (
(a + B(r - +1,8) d(vt)(l
- V)r vsldv) }
(22)
where torepresents anominallifetime, B(-) is the Euler
beta function, and a and b are constants (related to
background tumorrate andpotency, respectively). This
formula is linear in the dose-rate function d(t), but this
effective dose could be a nonlinear function of applied
dose; for example, ifthere was a nonlinear pharmacok-
inetic relation between the two.
Formulations like this, based on the idea of a single
cell going through five or six stages, are limited in that
they do not adequately describe how the fully trans-
formed celldevelopsintoatumor. Subsequentbiological
theories ofcarcinogenesis have described cell transfor-
mationasatwo-stage, oratmost, athree-stageprocess.
In the first stage the cell is initiated, a process usually
thought to require a mutation; in the later stage(s) the
cellbecomes fullytransformed throughaprocessofpro-
motion, forwhichmanydifferentmechanismshavebeen
proposed. This leads naturally to attempts to divide
carcinogens intoinitiators and promoters. Initiators are
assumed to act on the normal cell, or on an early trans-
formed stage, and may thus be described as early car-
cinogens; promoters are assumed to act on a later stage
and are late carcinogens. Further, initiators are ex-
pected to cause mutations in appropriate test systems,
but promoters are not. A complete carcinogen can act
at each stage, either because it is a mixture (such as
cigarette smoke) ofinitiator(s) and promoter(s), or be-
cause even as a pure chemical it can perform either
function.
Armitage and Doll (41), Moolgavkar and Knudson
(42), and others have developed two stage models in
which cells which are not fully transformed can prolif-
erate. These are discussed in the reviews mentioned
previously (10-12).
GENERALIZED MULTISTAGE. Various generaliza-
tions ofthe multistage idea can be attempted, but their
relevance to analysis of dose-response data from ex-
periments canbe questioned. Toillustrate, considerthe
following generalization.
Assume that a cancer arises after a sequence of n
events have occurred in a cell-possibly a sequence of
DNA damage events incorporated into the genome. If
four possibilities are allowed for a given cell (mitosis,
death, another event in the sequence, and repair ofthe
previous event), one can write the probability ofone or
more cells being in the state in which k events have
occurred by age t as Qk(S,t) evaluated at s = 0, where
Qk(s,t) satisfies the partial differential equation:
=t kk(1-e )+Ak,-. +
14(l- e+S)J * - -J , {=}
(23)
Here 4k is the probability per unit time for binary di-
vision; Rk iS the probability per unit time for cell death;
Xk is the difference between the transition rate from
state k to state k + 1 and the repair rate from state
k + 1 to state k.
Thismodelincorporatesrepaironlybetweenadjacent
states, butitcouldclearlybeextendedtodealwithmore
than two types of damage at the same time. The tran-
sition rates between states may depend on the dose of
carcinogen, the division rate, and other factors. For-
mulae including some of these complexities have been
written down by several authors. This one is written
here simply as an illustration, not to encourage its gen-
eral use. To use it would require an enormous amount
of information, on at least 3r-2 parameters, all as a
function of age (and in the case ofthe transition rates,
and possibly death rates, as a function of dose also).
Obviously, there would never be enough data to esti-
mate all the parameters from a statistical fit to exper-
rimental bioassay data. To even attempt use ofthe for-
mula would require finding far more information (for
example, on cell division rates), most of which is not
currently known.
POLYNOMIAL FORMULAE. Many of the dose-re-
sponseformulae, especiallythoseusedforextrapolating
risk estimates to low dose, can be derived as special
cases from multistage models. There are two common
ways of modifying the simple formula given by Armi-
tage and Doll in their 1954 paper (Eqs. 16 and 17).
1. Write transition rates explicitly as linear functions
ofthe carcinogen dose rate (d):
Ax =a +bid (24)
[Armitage and Doll (37) suggested the use of a linear
relationship, but did not write the explicit formulae.] If
a particular stage can occur only in the presence ofthe
carcinogen, [i.e., the background rate for the stage is
zero (ai = 0)], then Xi = bid; conversely, if the carcino-
gen cannot affect the occurrence of a particular stage,
then bi = 0 and Xi = ai. Substituting ai + bid for Xi in
Equation 17 gives
I(t,d) = (a, + bid)) tr'/(r - 1)!
(25)
It takes time for a transformed cell to give rise to an
observable tumor. Ignoring this consideration, an
expression for the probability of a cancer by age t can
be obtained from Equations 18, 20, and 25,
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p(d,t) = 1- exp f-k (l(ai + bid)) trl
=1 (26)
where extra constants have been absorbed into k and
it is assumed that the dose rate d is constant over the
lifetime.
When an analysis is always performed with datafrom
lifetime experiments, the age t in Equation 26 may be
treated as a constant and the dose-response formula
simplified to
p(d)= 1-exp-(qo +qi * d+ q2 * d2 + * )
qi 0 (27)
which at low doses reduces to a simple polynomial
p(d) =uo+ul -d+U2
- d2 +... U > .0
(28)
Strickly speaking, Equation 27is only an approximation
to Equation 26, since it does not take account ofall the
relationships expected between the qi obtained when
the polynomial in Equation 26 is expanded. However,
itisused as aheuristic dose-response curve, notinorder
to obtain the ai and bi in Equation 26.
2. A second common modification of the Doll-Armi-
tage formulation explicitly includes the time it takes for
a single transformed cell to give rise to an observable
tumor. Most analyses assume this time to be indepen-
dent of dose, and very often the time-to-tumor or la-
tency period is assumed to be a constant, w. If in ad-
dition, the time it takes to fully transform a normal cell
follows the Doll and Armitage form given in Equation
17, the probability of tumor at time t is given by
p(d t = 1 - exp (-k ((ai + bid))(t - w)r;
(29)
where the product is often treated as before as a simple
polynomial with positive coefficients. Once again, de-
rivation ofthis formula has assumed constant dose rate,
and once again, if the age t is assumed to be constant,
the term in the exponent is reduced to a polynomial in
dose rate.
THE EPA's MULTISTAGE APPROACH. The multi-
stage formula used by the EPA to determine safe ex-
posures to carcinogenic chemicals is that given in Equa-
tion 27. Computer programs are available to solve for
the parameters ai in Equation 27 (39,43). Ifthe animal
bioassay data under analysis has n dose groups, it is
possible to fit terms in the polynomial up to d -1, with
each term constrained to be positive. However, if the
resulting dose-response formula does not fit the exper-
imentaldata verywell, theresultsfromthe highestdose
group are omitted, and the procedure repeated until a
satisfactory fit is obtained (44). The excess risk caused
by a dose d in Equation 27 is dominated by the term
linear in dose at sufficiently low doses, so the EPA
approach is to find an upper confidence bound on the
estimate ofq1, and use this to extrapolate to low doses.
The EPA selected this approach because ofits built-in
conservatisms, but the dose-response formula used
clearly cannot adequately represent some (observed)
dose-response relationships. For example, Equation 27
impliesthattheprobability oftumorwillapproachunity
at sufficiently high doses. Vinyl chloride provides a
counter-example for this feature of the formula. The
bioassay data showed a maximum probability oftumor
(alltumors) ofabout 40% at high doses, and amaximum
probability for angiosarcoma alone of about 20% (Fig.
5).
TIME-TO-TUMOR MODELS. Latency periods can be
fairly easily incorporated into multistage models; Equa-
tion 29 represents one way ofincorporating a fixed pe-
riod between the causal event and its manifestation. If
the latency period can only be specified by a probability
distribution, with density functiong(T) atlatencyperiod
T, the resultant model can be obtained as a convolution
of this density function with the incidence function for
fixed latency period. For example, if the incidence for
fixed latency period T is
I(r,t) ~ f(d)h(t - r) (30)
[cf. Eq. 29 where h(x) = xr- andf(d) is a polynomial
in dose rate] then the incidence with a distribution g(T)
for latency periods will be
t
I(d,t) f(d)g(r)h(t - r)dr
=f(d)G(t) (31)
where G(t) will depend on the parameters describing
g(T) and thus may be estimated from data. This descrip-
tion assumes a constant dose rate, andf(d) might well
be a polynomial in this dose rate d. [For examples of
such forms, see Peto and Lee (45) and Hartley and
Sielken (46).] If the dose rate is not constant, the for-
mulation is more complicated to write (although still
mathematically straightforward), and much more dif-
ficult to use in the analysis of data.
Mixed Approaches
The current standard practice in estimating cancer
risks is to postulate first, that one of the formulae de-
scribed above (or a similar one) can adequately repre-
sent a dose-response relationship over some range of
doses where excess tumor incidence is high enough to
be observable, and second, that at lower doses this for-
mula will provide either a good estimate or an upper
bound to the excess probability oftumor. Using exper-
imental data then allows estimation of the parameters
of the chosen formula, which in turn allows extrapola-
tion (strictly, an interpolation; we shall not distinguish
the two here) to the lower doses.
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In addition to data from long-term animal studies,
there is much information relevant to dose-response
modeling which is now formally ignored because it is
unclearhowitshould orcouldbeincluded. Forexample,
some chemicals are known to increase rates of cell di-
vision but apparently do not act as initiators (they are
not mutagenic, or only very weakly so, in current test
systems). Ifthe multistage descriptionis tobecredible,
suchchemicals shouldaffecttumorratesonlyindirectly,
and the formulae derived by assuming a direct effect
on transition rates between stages should not be appli-
cable. However, it is still unclear whether the models,
and hence the formulae, should be modified for these
chemicals; in particular, it is unclear under precisely
what conditions such modifications should be made. An-
other example of information that is currently not in-
corporated in models is that on the pharmacokinetics of
carcinogens. This information is generally acknow-
ledged as important, butitsuse inestimatingrisks from
carcinogens is still controversial. However, there has
been much recent interest in formally incorporating
known pharmacokinetic details in cancer models.
The Pharmacokinetic Models. The formulae ob-
tained above have been derived to allow interpolation
between doses. The structure of such fornulae were
guided by mathematical models based on descriptions
of the biological processes involved, but in most cases
the parameter values in the formulae were ultimately
to be obtained from experimental data on tumor inci-
dence alone. The aim of a pharmacokinetic model, in
contrast, is to describe some parts ofthe process using
pharmacokinetic parameters measurable in subsidiary
experiments; in particular, the model aims to obtain a
better approximation to an effective dose rather than
relying on the applied dose. The hope is that there is a
simple relationship between excess tumorincidence and
the effective dose, a relationship that extends even to
very low effective dose. This approach has been used
to explain, for example, the observed dose-response re-
lationship for vinyl chloride. The first priority was to
understand the metabolism of vinyl chloride (47-50),
thentomeasure inauxiliarytests onratstheproduction
of metabolites as a function of vinyl chloride dose. It
wasfound thatthe amount ofvinylchloride metabolized
does not increaseproportionatelywiththeinhaleddose.
An increasing fraction is exhaled because the oxidation
pathway responsible for the activation ofvinyl chloride
to a chemically active metabolite becomes saturated.
When the fraction of animals with angiosarcoma was
plotted as a function of the metabolite concentration,
an apparently linear relationship (without saturation)
wasobtained, althoughGehringetal. (51,52)reportthat
this effective dose versus response plot was also con-
sistent with a probit formula. However, the concentra-
tion ofactive metabolite may or may not be linear with
applied dose at low doses, for no adequate measure-
ments of the metabolite at exposures comparable to
environmental exposures have been made. In addition,
the analysis did not consider the high mortality in high
treatment groups due to causes other than angiosar-
coma; this appears to have contributed significantly to
the downward curvatureinthe dose-response curve (N.
Gravitz, personal communication).
The relationship between applied dose and effective
dose (in this case, metabolite formation) is usually un-
known at low doses. Michaelis-Menten kinetics might
be assumed, and used to extrapolate tolowdoses. How-
ever, as Hill et al. (53) point out, experimental results
are frequently inconsistent with the Michaelis-Menten
formulation, especially when a wide range of concen-
trations are used. As a general approach, the phar-
macokinetic approach is clearly desirable as part ofany
attempt at low dose extrapolation, but it requires a
knowledge ofthe pharmacokinetics at low doses, iden-
tification ofthemetabolite(s) thatcausethetumors, and
still calls for the choice of a formula to represent the
relationship between metabolite concentration and re-
sponse. This information is also needed in applications
of the more general physiologically based pharmacoki-
netic model(s) (54), which take into account processes
of transport, absorption, and excretion, in additon to
metabolism.
Some ofthe Biological Information Required for a
Full Description. The multistage framework can in-
corporate pharmacokinetic mechanisms as well as sev-
eral additional ideas about carcinogenesis. Pharmacoki-
netic descriptions are usually used to estimate the
concentration of the ultimate carcinogen at the target
site, and the time dependence ofthat concentration, as
a function of the exposure, and so can be taken into
account inthe modelingofthe firststage ofamultistage
process. The multistage model can then be further ex-
tended to include more detail on cellular processes that
influence the genesis of cancer.
A complete formulation would include, at the very
least, details of the following:
1. Entry of the original material into extracellular
fluids and transport around the body.
2. Receptors on and transport through cell mem-
branes.
3. Receptors within the cytoplasm and transport
within the cell.
4. Reactions producingthe actualcarcinogen, e.g., cy-
tochromeP-450enzymeactivationreactions, aswell
as deactivation reactions.
5. Transport ofthe carcinogen throughout the cell.
6. Transport ofthe carcinogen across cellmembranes.
7. Transport of the carcinogen through extracellular
fluids.
8. Transport of the carcinogen through target tissue
cell membranes.
9. Receptors within the target cells and transport
throughout such cells.
10. Action on the DNA and other cellular components.
11. Repair mechanisms (e.g., for DNA and other tar-
gets) and their failures.
12. Cellular division rates, which may be affected by
the cytotoxicity of the chemical, and mechanisms
which act to prevent subsequent repair ofdamage.
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13. Other necessary effects before a cancerous cell is
generated.
14. Immune system responses of the whole organism
to the altered cells or products of such cells.
15. Cell to cell communication.
16. Growth rates of damaged cells.
This must not be considered a complete list; it simply
shows some ofthe expected complexity ofthe processes
which should be modeled. Clearly, many of the pro-
cesses can contribute to a nonlinear dose-response re-
lationship.
Steps 1 to 3 of this list represent initial entry and
transport of the material of interest. Step 4 is an acti-
vation step (ifnecessary). Steps 5 to 9 are some stages
of the transport of the carcinogen that may differ sig-
nificantly between species. Steps 10 through 15 repre-
sent the mechanisms that go into the microscopic dose-
response relationship. Ifthe chemical ofinterest is not
an initiator and/or does not interact with DNA, it may
nevertheless still be a promoter and so steps 1 through
9 are still relevant, as are steps 12 through 16.
One would expect to see quantitative species differ-
ences in rates of transport and in activation rates, for
example, but there may also be qualitative differences.
Steps 1 through 9 may combine in such a way that the
effective microscopic dose to the affected cell has a dif-
ferentrelationtothe externallyapplieddoseindifferent
species. Then the shape of the dose-response relation-
ship may differ from species to species. For example,
iftheenzymesnecessaryforanactivationstepareavail-
able only at much lower levels in one species, they may
be saturated in that species at much lower doses.
DNA Adduct Formation as a Measure ofEffective
Dose. Much of the work now in progress on pharma-
cokinetics is on the study of steps 1 through 9 of the
schema described. If carcinogenesis is indeed due to
direct action of the carcinogen on DNA, then it might
be hoped that a measurement ofthis action would give
avery good measure ofeffective dose. This would allow
a better description of steps 1 through 9, and, para-
doxically, might remove the necessity for modeling
these steps to obtain dose-response formulae by allow-
ing direct measurement ofthe effective dose instead of
the applied dose. One measure oftheactionofamaterial
on DNA is the production of DNA adducts, and such a
measure is one possibility for an effective dose.
The usually observed linearity between DNA adduct
formation and applied dose could be interpreted as
showing that in practice the effective dose is indeed
proportional to the dose applied to the animal. On the
other hand, Hoel et al. (55) suggests that the relation
between DNA adducts (possibly specific adducts rather
than total adducts) and cancers is likely to be linear,
but that the relation between applied dose and the ef-
fective dose (measured by DNA adduct concentration)
might be nonlinear because of nonlinear kinetic mech-
anisms. There are cases where there appears to be a
nonlinear relationship between DNA adduct formation
and applied dose. Figure 7 shows this relationship for
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FIGURE 7. Mean concentration of covalently bound formaldehyde
(209) in (a) the DNA, and (b) proteins, from the respiratory mu-
cosa, after exposure to varying concentrations of formaldehyde
(CH2O).
formaldehyde, where the DNA adduct concentration is
sublinear at low doses, even though the corresponding
curve for binding of formaldehyde to protein stays lin-
ear.
The studies of DNA adduct formation indicate that
forsomechemicalsthedose-responserelationforadduct
formation is linear, or very nearly so, over the very
wide range of doses from those at which tumors may
be observed in experimental animals down to those to
which humans may be exposed in the environment
(Figs. 8 and 9). Such a result could indicate linearity in
the combination ofsteps 1 through 10 above. However,
DNA adducts do not themselves represent a stage in
the development ofcancer, since they are a measure of
the total amount of DNA repair. It is presumably the
misrepair or nonrepair of DNA which forms one ofthe
stages in the process, not the total amount of repair.
Very small variations between DNA adduct formation
and unrepairable DNA damage can lead to very differ-
ent dose-response relations for tumor formation versus
dose (see the precautionary remark below). Without a
direct measurement of such unrepairable (or unre-
paired) damage, observation of total adduct formation
cannot provide sufficient sensitivity to detect possible
nonlinearity.
Nonetheless, it would be interesting to compare the
production of DNA adducts for different compounds at
different sites. The site and number ofadducts formed
may correlate well with the variation in carcinogenic
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benzo[a]pyrene (38,56)] in some target organ, it is ob-
served that the number ofDNA adducts formed within
that target organ is of order 1010 (i.e., about one per
million molecules of benzo[a]pyrene). The fraction of
animalsgettingtumorsinthetargetorganatsuchdoses
is oforder 0.1, so there is a ratio ofabout 1011 between
adduct formation and cancer as an end point (57). Sup-
pose there is one particular faultily repaired site on the
DNA, at which adduct formation and excision neces-
sarily leads to a tumor (or which is linearly related to
tumorformation). Thedose-responserelationforadduct
formation at this site, and hence for tumor formation,
could be highly nonlinear, for example:
b= 0.889±0.057
a= -3.267 n = (d/do)3
10 100
DOSE (ng/kg)
1000 (LOG SCALE)
FIGURE 8. DNA adducts of aflatoxin in cells of the liver (158) 1 hr
after administration of varying doses of aflatoxin.
where n is the total number in the target organ ofsuch
sites affected at dose d, and do is a typical dose which
causes observable tumors. Ifthere are also other, per-
fectly repairable sites with a linear dose-response re-
lation:
N = 1011 * (d/do)
z
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FIGURE 9. DNA adducts of benzo[a]pyrene in cells of the stomach
(56) 18 hr after administration of varying doses ofaflatoxin. 10-3
g/mouse corresponds to a dose of 30 mg/kg.
potency (as computed from high dose experiments in
animals). Without such a correlation, with high explan-
atory power, it would be unbelievable that the dose-
response curve for DNA adducts could be used as a
surrogate for a cancer dose-response curve. But even
ifsuch a correlation exists, one should stillbe extremely
cautious about using such a surrogate to extrapolate to
low doses.
DNA ADDUCTS-PRECAUTIONARY REMARK. If an
animalisfed adoseofcarcinogenwhich maybeexpected
to produce observable numbers oftumors [say 10 ,ug of
(33)
where N is the total number of sites in the organ af-
fected, then the overall dose-response relation between
total adducts and dose would be simply:
Total adducts = 1011 * (d/do) + (d/do)3 (
which is experimentally indistinguishable fromlinearity
(for doses below 104 *do, which would probably kill the
animal outright).
This example is given solely to point out the possi-
bility that there may be nonlinear dose-response rela-
tions hidden in the overall linear observations ofadduct
formation. Itwould be evidentthat one could substitute
practically any nonlinear term for the cubic term above
with the same result. The enormous factor of 1011 be-
tween the total adduct formation and the final response
of interest can hide practically anything. In particular,
the mechanism ofthis example is not the only one which
might be operating to cause a nonlinear carcinogenic
response even with linear DNA adduct formation.
There is some evidence for a two-step mechanism, with
cell division fixing the DNA damage in some way. If
the unrepairable DNA damage is produced linearly at
a low rate, but the rate of cell division is affected by
dose, then one could also obtain a nonlinear dose-re-
sponse relation for carcinogenesis.
Examples of Mixed Approaches. A COMBINED
PHARMACOKINETIC AND MULTISTAGE MODEL FOR VI-
NYL CHLORIDE. Bois et al. (58) describe the body by
compartments, into and out of which vinyl chloride is
transferred by blood flow. In each compartment the
parent compound is metabolized and the metabolites
and parent compound may be absorbed, circulated in
the blood, excreted, or detoxified. They may also be
bound on proteins or DNA. The model also allows for
some of the DNA adducts formed to be removed by
-
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0
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z
z
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-
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repair mechanisms. Michaelis-Menten equations are
used to describe activation, detoxification, and repair
processes, but binding is considered to be a first-order
process. The number ofbound DNA adducts is used as
the effective dose for the cancer process. The physio-
logic and pharmacokinetic components ofthe model are
similar to those developed by Ramsey and Anderson
(54).
The process of carcinogenesis is modeled by postu-
lating that cells are in one of three states, normal, in-
itiated, orcancerous, with cells inthese states growing,
dying, differentiating, and changing between states.
The transition rates between states are taken to be a
function ofthe DNA adduct levelin an organ. The prob-
ability that one or more cells are transformed to the
cancerous states corresponds to the probability of can-
cer.
The application ofthis model to vinyl chloride is dis-
cussed in "Vinyl Chloride."
A MULTISTAGE MODEL FOR SACCHARIN-INDUCED
BLADDER TUMORS. Greenfield et al. (59) have devel-
oped a two-stage model of carcinogenesis, which they
apply to the study ofbladder carcinogenesis. Three cell
populations, normal, initiated, and transformed, in-
crease or decrease in number according to mitotic and
transition rates which are allowed to vary in time. Cer-
tain predictions of the model are directly verifiable,
since it is possible to distinguish transformed cells from
theothertwotypes onhistological slides, sothatmitotic
rates and population sizes maybemeasured. Modelpre-
dictions can be matched with tumor data using various
assumptions for the transitions rates, and this proce-
dure has been used to test various hypotheses on how
saccharin increases the activity of FANFT (N-4[-(5-ni-
tro-2-furyl)-2-thiazolyl]formamide) (see "Saccharin").
Remarks
It is a common premise that cancer arises from a
single cell and that one or more mutations, caused di-
rectly by damage to DNA or by errors during DNA
replication or repair, are a necessary initial step in the
process of carcinogenesis; but this premise is not uni-
versally accepted (60,61). The relationship between ef-
fective dose and mutation frequencies is usually pre-
sumed to be linear, based on several examples oflinear
dose-response relationships for mutation in bacterial
systems, although there are some noted examples of
nonlinearity (e.g., nitrosamines). However, there are
other processes, such as mitosis, cell death, and inter-
cellular communication, which are alsoimportant in car-
cinogenesis but which this formulation ignores. Indeed,
Rubin (61)believesthatmutationplays aminorrole and
that cellularinteractions are much more important. The
dose-response relationship associated with such pro-
cesses would be expected to be highly nonlinear.
Intercellular Communication. Trosko (62) pro-
vides a description ofhow inhibited metabolic transfor-
mationmightpromotetheprocess ofcarcinogenesis. An
inhibited cell inthe healthy environment ofnormal cells
isunlikelytogiverisetoatumor, sincemostmammalian
genes exist in allelic pairs and the neoplastic phenotype
is usually recessive to the normal phenotype. For ex-
ample, when certain normal and transformed cells are
injected into nude mice, tumor growth is suppressed;
incellgrowthfusionstudies ofcertainnormalandtrans-
formed cells, normal hybrids result. Somehow normal
cells must exchange information with initiated cells.
This communication could be blocked by the carcinogen
or promoter. When blocking occurs, the initiated cell
proliferates. As the mass of initiated cells grows, fur-
ther genetic changes occur so that the cell itselfcannot
communicate and can metastasize.
Trosko has developed an in vitro assay to measure
the degree to which chemicals interfere with the met-
aboliccooperationofcells andhastestedatnoncytotoxic
doses many chemicals known to be promoters. He re-
ports an apparent threshold in the dose-response re-
lationships. Below the threshold the chemical does not
appear to affect the ability of cells to communicate;
abovethethresholdtheeffectincreaseswithdose. How-
ever, the importance ofthis result is uncertain because
the test is so new and is still being reviewed by the
scientific community; on this matter, Yamasaki (63)
claims that "there are no scientific data which indicate
the existence of a threshold dose [by promoters]."
True andSecondary Carcinogens. It has been sug-
gested that whereas true cancers are caused in healthy
individuals bydirect action onthe cell, other, secondary
cancers can occur when the body is severely damaged
or weakened. Other authors have used the words "di-
rect" and "indirect" instead of true and secondary.
These secondary cancers would be expected to have a
dose-response relationship similar to that of a toxic re-
sponse; i.e., a threshold type, such as may be modeled
by the probit formula. We mention here three (not mu-
tually exclusive) mechanisms.
1. Toxicity can affect the rate ofinitiation by increas-
ing the rate of fixation of DNA damage. Farber (1,2)
and others suggest that mutation is a necessary but not
sufficient step in the process ofinitiation. A cycle ofcell
proliferation may be necessary to fix the mutation. This
is well established for the liver and appears to be true
also for the bladder and pancreas. Regeneration rates
in these organs increase with the degree oftoxic insult.
This has obvious importance for the types of assump-
tions made in modeling initiation rates. Farber empha-
sizesthat, especiallyforquiescentorgans (e.g., bladder,
pancreas, liver, thyroid), the rate-limiting step for ini-
tiation may be cell damage and the regeneration that
results; although many carcinogens can interact with
DNA, only those that can induce reparative cell prolif-
eration, due to their cytotoxicity, are likely to result in
cancer. He emphasizes this relationshipbetween cancer
in these organs and chronic tissue damage.
We have found a statistical correlation between the
finding ofcarcinogenic effect in the NCI/NTP bioassays
and the chronictoxicity ofthe dose given inthese bioas-
says (40,64-66), and a similar correlation was reported
by Parodi et al. (67). However, there are many other
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plausible mechanisms that would give the same corre-
lation.
2. Bradley (68) has proposed that, inresponse to sub-
lethal toxicity, the cell releases the contents of some
lysosomes. DNA hydrolases contained in these lyso-
somes might enter the nucleus, causing single and dou-
ble DNA strand breaks. In cell culture of rat hepato-
cytes, a relationship between cytotoxicity and single
strand breaks has been found (69).
3. One of the toxic effects of a xenobiotic might be
interference with metabolic processes in such a way as
to alter the communications between cells. This could
reduce the efficiency ofthe immune system and reduce
the normal scavenging ofabnormal cells, allowing their
proliferation.
There are several carcinogens which might act
through such mechanisms. Benzene is only known to
cause leukemia in humans after the bone marrow has
been damaged bytoxic effects and pancytopenia has set
in. Bladder cancer, produced by saccharin and by some
industrial dyes, may be secondary to chronic irritation
of the bladder. The same might be true for formalde-
hyde and nasalirritation. Sixtypercent ofthechemicals
studied inthe NCI/NTP Carcinogenesis Bioassay series
have been found to be carcinogenic, but only 30% would
have been so found ifthe maximally dosed group were
omitted from the analysis (although this may simply be
a result oflower statistical power of such an analysis).
The observed correlation ofmeasured carcinogenic po-
tency and acute toxicity would be explained if a large
fraction of these chemicals (of order, half) were sec-
ondary carcinogens, but the data are inadequate to
make such a distinction.
Radiation Carcinogenesis vs. Chemical Carcino-
genesis. "Human Studies" and "Animal Studies" pres-
ent data on dose-response relations in animals and hu-
mans. Some of the discussion concerns the effects of
radiation, sincehumanexposureshavebeenwidespread
andmeasurements ofthese exposures areavailable. The
rest discusses the data on chemical carcinogenesis, usu-
ally from organic compounds. There are differences be-
tween radiation and chemical carcinogenesis, and these
differences are reflected in the theories and mathemat-
ical formulations ofdose-response relationships.
Radiationhastheabilitytopenetratecellsanddeposit
energy within them randomly and is unaffected by the
usual cellular barriers presented to chemical agents
(70). Furthermore, while radiation carcinogenesis in-
volves the formation ofreactive oxygen species by the
process of ionization, no metabolic activation step is
required, so that the cellular machinery for such acti-
vation is not required. Cancer induction from external
radiation exposures (e.g., X-rays) canbedescribed sim-
ply, since carcinogen distribution, excretion, and bioac-
cumulation, which might contribute to the nonlinear
structures of dose-response relationships, are absent.
Any observed nonlinearities thus have fewer possible
explanations, although the list is still fairly long, e.g.,
dose-dependentrepair, multiplehits, cellkillingand cell
scavenging. Exposure to internally deposited radioac-
tive compounds is complicated by distribution in the
body, bioaccumulation, and radioactive half-life. How-
ever, dose is usuallymeasured bythe amount ofenergy
per unit volume (rads) delivered to a particular target
site; so, in contrast to chemical carcinogens, dose is
already presumably in units ofeffective dose.
A distinction isgenerallymade betweenhigh and low
LET radiation. LET, or Linear Energy Transfer, is a
measure ofthe average amount ofradiation energy de-
posited per unit distance that the radiation travels
(track length) where conventionally, energy is meas-
ured in units of 1000 electron volts (keV) and length in
microns (,um). High LET radiation energy is typically
dissipated incells atsurfaces (e.g., alpharadiationfrom
radon daughters) and low LET radiation is deeply pen-
etrating(e.g., X-rays). Physiciststendtoemphasizethe
effect on the radiation and use the expression "energy
loss" or "dE/dx" instead of LET.
For high LET radiation at high doses there are sev-
eral examples where the dose-response relationship ap-
pears superlinear. This is usually attributed to cell kill-
ing (71); however, similar saturation effects are
observed in cell culture in which only surviving cells
are assayed. Thus, the superlinearitycannotbe entirely
due to sterilization, but perhaps to "some form of cell
selection associated with cell killing" (72). In any event,
the mechanisms are apparently quite different from
those observed for chemical carcinogenesis.
For low LET radiation, it has been postulated that
two nearly simultaneous hits on a cell are required to
produce a single mutation (anevent initiatinga cancer).
This would lead to a dose-response relationship that is
quadratic in dose, and so sublinear. For high LET ra-
diation, a single hit is supposed to be sufficient, leading
to a linear dose-response relationship. Cohen (73) has
reviewedthe variouslines ofevidence supportingasub-
linear dose response for exposure to radiation at low
levels. In some experiments a given dose is less carcin-
ogenicwhenspreadoutintimethanwhengivenacutely,
suggesting that damage produced at low dose rates is
more fully repaired than that produced at high dose
rates. There have been various explanations for this
phenomenon, but one is to postulate that single strand
chromosome breaks are easily repaired, while repair of
a double strand break, much more prevalent at high
dose rates, is difficult and faulty. High LET radiation
is found to bebiologically more damagingthanthe same
dose of low LET radiation. Since high LET radiation
concentrates damage on a much smaller volume of tis-
sue, it is more probable that multiple hits will occur
within a small region. Assuming that two unrepaired
hits within a smallregion are required foranyinitiation
step, Cohen suggests two possibilities: double hits may
be made either by the same or by separate particles.
The number of double hits is proportional to the dose
if the hits are by the same particle, whereas it is pro-
portional to the square of the dose if two particles are
required.
Atlowdosesitisunlikelythattwoparticleswillstrike
the same sensitive volume and so a double hit occurs
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mostly because a single particle acted twice within a
small region. This leads to a linear dose-response re-
lationship in the low dose region. At higher doses, dou-
ble hits from two particles become likely, so here a
quadratic term predominates. The precise point at
which the quadratic effect begins to dominate depends
onthe type ofradiation and whatconstitutes asensitive
volume. As arule, theobservation ofaneffectquadratic
in dose should occur at much lower doses of low LET
radiation, since it is much less likely that, at a given
energy, asingle low LETparticle willdeliveramultiple
hit. For the very high LET alpha particles, which
mostly deliver multiple hits, no dose-squared effect is
expected. Animal studies are consistent with this view:
Data on cancer caused by exposure to X-rays, gamma-
rays, and beta-rays frequently indicate upward curva-
ture for external radiation and internally absorbed
radionuclides; alpha particles appear to give a linear
relationship at low doses. In "Human Studies" we dis-
cuss how well human data agrees with this simplified
treatment.
Human Studies
Introduction
Information on excess human cancer incidence and
the exposures leading to it is rarely sufficient to char-
acterize a dose-response curve, and never as complete
as desirable. The best data available are for cases in
which modulating factors have been identified as im-
portant (74). Aflatoxin B1, for example, is known to
consistently induce liver cancer in animals, but appears
to be a cause of cancer in humans only when there is
simultaneous exposure to the hepatitis B virus, or in
the presence of cyles of famine and plenty. Human
esophageal cancer can be related to alcohol intake, but
is most prevalent in alcoholics who smoke heavily (75).
There are no human data good enough, nor can any
conceivably be good enough, to directly estimate the
dose at which excess lifetime risk is of order 10-6 to
10-i, which are values typically demanded in regula-
tion.
The best set ofhuman dataisthat obtained in a study
of cigarette smoking in British physicians. Over the
range of4 to40 cigarettes perday, the incidence oflung
cancer is adequately described by a quadratic function
in the number ofcigarettes smoked daily. Lungcancers
caused by occupational exposures to coke oven emis-
sions canalsobedescribed byanonlineardose-response
function with upward curvature. The similarity is per-
haps not surprising since coke oven emissions contain
many active constituents also present in cigarette
smoke. Despite voluminous data on human cancers
caused by radiation, conflicting hypotheses of sub-,
super-, and purely linear dose-response relationships
cannot be ruled out, especially for low-dose exposures.
For low-LET radiation, the dose-response relationship
appears sublinear in the low dose region, superlinear at
high doses, and linear in between. For high-LET ra-
diation, dose fractionation mayincrease response above
that for the same total dose given in a single exposure,
correspondingto asuperlinearrelationship between re-
sponse and dose rate.
For exposures to several different materials, the
dose-response curve obtained in human studies appears
to be sublinear. The nonlinearity is seldom strong
enough to be statistically significant, however, and may
be an artifact ofthe analysis. When cumulative dose is
used as the indicator ofexposure, there is a strongbias
toward such nonlinearity ifincomplete account is taken
ofthe age ofexposure and the age distribution ofthose
exposed (e.g., see"CokeOvens"and"LungCancerfrom
Exposure to Radon Gas"). On the other hand, if the
dose-response curve is truly sublinear (so that it rises
more rapidly than linearly with dose), but the mea-
surements ofdoseandresponseareuncertain, thensuch
measurements would indicate a dose-response relation
whichisapparentlymorelinear(76). Anunbiasedanaly-
sis requires complete and accurate exposure and out-
come histories for each person at risk. Most studies fall
short ofthis, but nevertheless provide useful informa-
tion, especially when the size and direction ofthe bias
can be estimated.
In reviewing the data, we have found it useful to fit
various formulae to the experimentally observed dose-
response curves in order to make consistent compari-
sons. Unless otherwise noted, such fits are our own,
not those ofthe original authors.
Cigarettes
British Physicians. There are now many epide-
miologicalstudiesthatcorrelateincreasesinlungcancer
risk with the number of cigarettes smoked and other
smoking characteristics (77). The most informative
dose-response relationship is obtained from the study
oflung cancer incidence in British physicians begun by
Doll and Hill (78), and continued by Doll and Peto (79).
In this study, the subjects were from a well-defined,
uniform population, with good health records and ac-
curate statistics, and the analysis carefully took into
account the age and time dependence of tumor devel-
opment. The relationship between the average number
ofcigarettes smoked daily (dose rate) and the incidence
of lung cancer, standardized for the age of the physi-
cians, was characterized by a function approximately
quadratic in dose rate (79).
Lung Cancer Incidence oc (cigarettes/day + 6)2
(35)
This fits better than the best linear fit (p< 0.01 for
curvature), although a straight line fits reasonably well
(Fig. 10) and was the initial preference (78).
The data on cigarette smokers are so extensive that
the effects of different ages of starting and stopping
smoking can be distinguished, and matched with a bi-
ological model. Apparently cigarette smoke acts both
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FIGURE 10. Age standardized tumor incidence associated with the
smokinghabits ofBritishphysicians (79). (98% confidence intervals
shown about each point.)
as an early and a late stage agent (76,80). This might
be expected, since cigarette smoke contains a mixture
of initiators, promoters, and complete carcinogens (as
determined in animals and in vitro experiments).
Tar Exposure vs. Incidence. An alternative mea-
sure ofthe dose ofcigarette smoke, total tar exposure,
has been used to study the effects of smoking (81-84).
Lifetime tar exposure was estimated by counting life-
time cigarette consumption and weighting by the tar
content of the cigarettes smoked. Relative risks were
obtained by comparingsmokinghistories from Austrian
lung cancer victims to those from hospital patients ad-
mitted for nonsmoking-related problems. Such relative
risks are proportional to incidence, so that relative risk
may be used as a surrogate for incidence.
Table 2 and Figure 11 illustrate the results obtained
for two different types of lung cancer, squamous cell
carcinoma (SCC) and Kreyberg I. The dose-response
function appears to curve up in the region of low tar
exposure and level offat high exposure. Fitting alinear
function overestimates the relative risk at low doses,
but grossly underestimates it at high dose. This behav-
ior is especially pronounced for the squamous carcino-
mas. Kunze and Vutuc give the estimated relative risk
for each dose group, but do not report sufficient infor-
mation to assess the uncertainties of these estimates.
Consequently, we cannot correctly weight each data
point when fitting various formulae to these data.
Nevertheless, in an attempt to discover whether there
is any significant curvature in the dose-response curve
at low doses, we fitted two alternative formulae using
maximum likelihood techniques and assuming equal
weightingforeach point. The first formula was asimple
quadratic curve, withthe high dose points omitted from
the fit. The second, usingall the data, used the formula:
Relative Risk - 1 = (B D + C. D2) exp(-A * D))
(36)
(This formula has been used to analyze dose-response
data, especially for radiation-induced cancers, in which
the response levels off or falls at high doses. It is jus-
tified by an assumption that the high dose behavior is
due to some such mechanism as cell killing, affecting all
cells.) The estimated parameters forboth formulae sug-
gested a sublinearity at low dose, consistent with the
findings of Doll and Peto, but this nonlinearity could
well be an artifact of our procedure. The leveling offof
response at high doses might have been due to overre-
porting of cigarette consumption by heavy smokers.
Doll and Peto (78) found that those claiming to smoke
morethan40cigarettes perday wereinaccurate intheir
estimates.
Coke Ovens
It has been suggested (85,86) that the dose-response
relationship between coke oven emissions and lung can-
cer is nonlinear. Mazumdar et al. (87) estimated cu-
mulative exposures for 8000 coke oven workers and
compared these with their medical histories. If we fit
polynomial formula to the raw Mazumdar et al. figures
for age adjusted lung cancer incidence and cumulative
exposure to coal tar pitch volatiles, a highly significant
quadratic coefficient results, indicating strong upward
curvature (Fig. 12). Such an exercise is misleading be-
cause cumulative exposures are not independent of age
at entry into the cohort, length of exposure, or, most
important, length of observation. The workers in the
highest exposure groups were older, exposed longer,
Table 2. Relative lung cancer risk versus tar exposure at ages 51 to 60 years (81).
Tar exposure (arbitrary units)
Tumor type <500 501-1000 1001-2000 2001-3000 3001-4000 4001-5000 >5000
scca 3.3 3.3** 30.1* 39.9* 48.1* 30.9* 56.9*
Kreyberg I 1.0 4.1** 15.7* 21.5* 20.8* 17.1* 21.5*
Total 4.3 7.4 45.8 61.4 68.9 48.0 78.4
aSquamous cell carcinoma.
*Significant at p < 1%.
**Significant at p < 5%.
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FIGURE 12. Age standardized incidence oflung cancer in coke oven
workers versuscumulative exposure to coaltarpitchvolatiles (87).
aSignificantly nonlinear (p <0.01). bCoal tar pitch volatiles.
and cancers caused by earlier exposures to both coke
oven emissions and cigarettes, which this studyignores,
had more chance to develop.
An attempt has been made (85) to adjust approxi-
mately for the variable observation period by assuming
a simple model which included a latency period. Ex-
posures during one latency period prior to the time of
observation were ignored, and exposures during the
next 10 years preceding were given less weight than
the earliest exposures. With such assumptions, it was
foundthat asthe assumedlatencyperiodwasincreased,
the dose-response relationship appeared more linear.
With an assumed latency period of 15 years, a linear
formula fits better than the nonlinear ones. Since lung
cancerincidence increases roughlywiththe sixthpower
of age (37), these observations are consistent with a
multistage carcinogenesis modelwithjust one stage lin-
early affected.
There are at least two ways to check whether the
coke oven datatruly demand a nonlinear dose-response
relation. The best would use the original data on the
8000 workers studied to analyze how incidence varies
with age, exposure rate and duration, and time from
exposuretoobservation. Analternative, easier, butless
satisfying check would be by simulation. Using as-
sumptions about the age distributions and dose rates
forthe different cumulative exposures in the datagiven
in Mazumdar et al. (87) and Land (88), one could com-
pute that the number ofcancers expected were the true
dose-response relation to be represented by Equation
26, with just one term linear in dose, as expected for a
simple multistage model, and compare this with the
observed number.
Radiation
Four large, widely reviewed reports discuss dose-
response functions for radiation: the 1980 (BEIR III)
Committee on the Biological Effects of Ionizing Radia-
tion Report (71), the 1972 BEIR I Committee report
(89), The National Council on Radiological Protection
and Measurement (NCRP) report on radon (90), and
the report of the Working Group to Develop Radioe-
pidemiological Tables (91). The last report contains ta-
bles which assign probabilities that a particular cancer
was causedby agiven exposure toradiation (sometimes
called probabilities of causation). A short review has
been provided by Kohn and Fry (92), and Upton (72)
and Cohen (73) provide more extensive discussions of
the effects oflow doses. These reports contain a careful
and extensive review ofthe literature. We concentrate
on those cases where there is sufficient information to
make some statement about dose-response functions
and see what generalizations can be drawn from these
cases. Unless otherwise indicated, the information used
in this section can be found in the reports ofthe BEIR
Commmittee and ofthe NCRP.
The effects ofexposure oflarge populations to levels
ofionizingradiationabovebackgroundhavebeenwidely
studied and documented (Table 3). When exposure has
been used formedical purposes, exposure data are usu-
ally reliable, although follow-up is seldom perfect. Oc-
cupational exposures and doses received from atomic
bomb explosions are not as wellmeasured. Researchers
at Lawrence Livermore Laboratory have recently re-
calculated the doses received in the Hiroshima and Na-
gasaki explosions, so that older reviews on dose-re-
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Table 3. Some cases of human exposure to ionizing radiation.
Source of exposure Exposure
Bombs:
Hiroshima, Nagasaki Single large exposure
Bikini Atoll, Nevada tests Short exposure period
Medical treatments:
thorotrast Single large exposure
common X-ray exams A few small exposures
X-ray treatments:
scalp epilation Single large exposure
ankylosing spondylitis 1-5 times week for 2
weeks-2 months
fluoroscopy (tuberculosis exam; A few to hundreds of
postpartum mastitis treatment) exposures
X-ray in pregnancy (childhood A few small exposures
leukemia)
Radium injections for ankylosing Several injections over
spondylitis and tuberculosis various periods up to
4 years
Occupational:
radium dial painter Continuous
underground miners (radon gas) Continuous
nuclear workers: Hanford; Britain Continuous
medical personnel Continuous
Environmental:
area ofhigh natural background:
Kerala, India; China; Brazil Continuous
indoor air (radon gas) Continuous
Table 4. Human cancers induced by ionizing radiation.
Relative importance Sites
Major Female breast, thyroid, lung,
leukemia, alimentary tract
Minor Pharynx, liver and biliary tract,
pancreas, lymphomas, kidney
and bladder, brain and nervous
system, salivary glands, bones,
skin
Magnitude ofrisk uncertain Larynx, nasal sinuses,
parathyroid (tumors), ovary,
connective tissues, prostatea
Radiation-induced cancer not Uterusa and cervix, testis,a
observed mesentery and mesothelium,
chronic lymphatic leukemia
aCancers of reproductive tissue are not generally associated with
radiation exposures (71); however, arecent studyofBritish nuclear
workers (albeit with only a small number ofcases) found increased
relative risk for testicular, uterine, and ovarian cancer, although
none of the increases were statistically significant (207,208).
Surprisingly, incidenceofprostate cancerwassignificantlyelevated
(p < 0.001), with incidence increasing with exposure.
sponse relations must be considered in the light ofthe
new dosimetry.
Quantity and Quality of Various Radiation Expo-
sures. Radiation is known to cause a variety ofhuman
cancers, and is suspected of causing others (Table 4).
Different tissues are affected to different extents, with
responses depending on the type and qualities of the
radiation and onthe circumstances ofexposure. Various
other measures of biological damage similarly depend
strongly on radiation quality (72). An example is the
varying chromosomal damage (93) occurring at equal
absorbedradiation doseforradiations ofdifferentlinear
energy transfer (LET) (Fig. 13 and Table 5), and even
acute lethal effects vary to a similar degree (94). As for
chemical carcinogenesis, it is unlikely that the shape of
the dose-response curve is the same for all tissue types
and types and qualities of radiation. Human cancers
have been shown to occur in several different tissues,
but for only a few are the data good enough to attempt
any dose-response modeling.
High Doses. BREAST CANCER. The relationships
between absorbed dose and breast cancer seen in
women exposed to radiation are linear at excess risks
of order 1 to 5%. Figure 14 shows data on four groups
of women: Japanese atomic bomb survivors, New York
women given X-ray treatment for postpartum mastitis,
and Massachusetts and Nova Scotia tuberculosis fluo-
roscopy patients. For the atomic bomb survivors, a lin-
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FIGURE 13. Variation in the predicted number of chromosome ab-
errations (above the background number) with average linear en-
ergy transfer (LET), at a constant absorbed dose ofone rad (93).
Table 5. Chromosome aberrations per cell above background per
rad of exposure.
Approximate LET,
Type ofexposure Yield/cell, x 104 keV/,um
15 MeV electrons 0.61 ± 1.12 NA
15 MeV electrons,
pulsed 0.96 ± 1.92 NA
'Co y-rays 1.62 ± 0.29 0.2
250 kVp x-rays 4.82 ± 0.54 2
14.7 MeV neutrons 26.3 ± 4.0 12
Cyclotron neutrons
(E = 7.6 MeV) 47.9 ± 3.3 19
252Cf neutrons
(E = 2.13 MeV) 60.0 ± 1.9 40
Fission neutrons
(E = 0.9 MeV) 72.8 ± 2.4 60
Fission neutrons
(E = 0.7 MeV) 83.5 ± 1.0 73
"9Pu 5.15 MeV
Alpha particles 37.5 ± 2.4 170
?A2Cm 4.9 MeV 28.6 ± 1.5 190
aCalculated from the data of Edwards et al. (93).
bPlus or minus one SE.
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FIGURE 14. Breast cancer incidence in women exposed to ionizing radiation (71).
ear dose-response relation was expected for the high-
LET neutron dose component and nonlinear dose-re-
sponse relation for the low-LET gamma dose compo-
nent. This is not observed, for the best fitting model is
linear in gamma dose. In Table 6 are the results ofthe
BEIR Committee's attempts at formula fitting. They
tried four different formulae: linear [F1(D) = ao + a,
D]; linear quadratic [F2(D) = ao + a, * D + a2 D2];
Table 6. The shape of the dose-response curve for breast
cancer.a
Series Best fit
A-bomb survivors No function fits significantly
better than F1. Where risks
are statistically significant,
data supports low dose
linearity for those results
corresponding to approximately
1% excess risk.
Massachusetts fluoroscopy Linear model (F1) fits well;
upward curvature suggested
(F2: a2 > 0), but not
statistically significant
(p = 0.36).
Mastitis (dose to single breast) Linear with significant cell killing
component (p = 0.01 for b in
F3).
Nova Scotia fluoroscopy Linear fit (F1) with no downward
turn at high doses.
aF represents the risk, D the dose. F1 (D) = aO + a, * D, purely
linear; F2 (D) = aO + a, * D + a2 * D2, linear-quadratic; F3
(D) = FiebDt, linear with cell killing.
linear with an assumed cell death term at high doses
[F3 = F1 * exp(- * D2]; and linear quadratic with cell
death [F4 = F2exp(- D2]. Thequadraticterms were
not significant in either of the cases tried, and the cell
deathterm wassignificantonlyforthemastitispatients.
The BEIR Committee also noted that the results are
only dependent on cumulative dose; dose fractionation
does not appear to matter.
THYROID. Thyroid cancers have been produced
when X-rays were used medically in the treatment of
pertussis, enlarged thymus, acne, hemangiomas, and
ringworm, but none with the medical use ofradioactive
iodine. External X-radiation may be more efficient at
inducing thyroid neoplasia than the internal exposure
due to the iodine isotopes used medically, but the avail-
able data are also consistent with equal efficiency (95).
The different dose rates and energy distribution within
the thyroid may also contribute to this apparent differ-
ence between tumorigenic efficacy ofX-rays and radio-
iodine. Inthe cumulative dose range of615 to 1500rads,
the dose-response relationship for X-ray induced thy-
roid cancers appears to be linear, but at lower doses
the data are inadequate to distinguish between alter-
native hypotheses.
LUNG CANCER FROM EXPOSURE TO RADON GAS.
Lung cancer has been associated with radiation expo-
sures in three groups: patients given radiotherapy
treatments for ankylosing spondylitis, Japanese atomic
bomb survivors, and underground miners. In the first
two groups radiation was distributed over much ofthe
body, but the underground miners were irradiated pre-
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dominantly in the lung by inhaled radon gas and radon
daughters. Only for the last group are there sufficient
data to obtain dose-response curves. These have sug-
gestions ofnonlinearity, but are mostly consistent with
a linear relationship.
A lung disease peculiar to miners working the silver
and copper mines ofCentral Europe was first described
as early as 1500 A.D. and called male metallorum by
Paracelsus. It was not until the early 1960s that the
etiological role of radon was accepted for lung cancers
found inunderground miners (90). Radon daughters are
the products of radioactive decay of radon gas, which
escapes from the surfaces offractured rock. The daugh-
ters adhere to dust and may then be inhaled and de-
posited in the lung. Here they decay further, giving off
high LET alpha radiation which is absorbed by the cells
just at the surface [within 10tm (96)] ofthe lung.
Thedataonoccupationallungcancers inunderground
miners have been extensively reviewed (71,90). A sum-
mary of this data is shown in Table 7 and Figures 15
and 16. The unit ofexposure used is the working level
month, which for underground miners is equivalent to
approximately0. 5rad (absorbedalphadosetothebron-
chialmucosa). One workinglevelcorresponds toaircon-
taining short-lived radon daughters ofany isotopic mix
with a potential alpha radiation energy release of
1.3 x 105MeV/L. Breathing such air for one working
month (170 hr) results in an exposure of one working
level month, abbreviated WLM.
Absolute excess risk of lung cancer is plotted (Fig.
15) against exposures for the six groups listed in Table
7. Figure 16 shows the data at higher doses for U.S.
miners. Also shown are fitted curves (a polynomial for-
mula), all ofwhichgive some evidence forpositive quad-
ratic or higher order terms in the dose-response rela-
tionship at the lower doses (except for the
Newfoundland data, where there are only two data
points). The differences from linearity are statistically
significant for the Czech, Canadian group 1, and Swed-
ish miners.
The observed excess lung cancer incidence at a given
dose above 200 WLM differs substantially among the
various groups of miners. This might be a result of
differences in the age distribution of the study popu-
lations; of differences in techniques for measuring ra-
diation exposures; of differences in exposure to ciga-
rettes and other lung carcinogens; or of other
differences between the populations. The exposure es-
timates for the U.S. Colorado miners were obtained
from few measurements, with many estimates made
indirectlyfromminesin otherlocations. Overestimation
of exposure may have been systematic (97), leading to
underestimates of risk per WLM. The dose-response
data from U.S. mines is nevertheless consistent with
observations of Chinese (predominately nonsmokers)
living in areas of high background radiation who ex-
perience an excess exposure to radon gas of approxi-
mately 0.14WLM/year (see "Areas ofHighBackground
Radiation"), although the age distributions ofthese two
groups are substantially different.
Table 7. Excess risk of lung cancer in miners exposed to radon
and radon daughters.
Expected
Excess risk/106 cancers/104
Exposure person-year
(WLM) WLM
United States uranium miners
Colorado plateau region
60 - 3.1 (5.6)
180 8.0 (4.4)
300 7.8 (3.5)
480 7.8 (2.2)
720 2.7 (1.3)
1320 4.0 (0.7)
2760 2.8 (0.4)
7000 3.0 (0.6)
Czechoslovakian uranium miners
72 4.6 (3.6)
124 11.2 (3.1)
174 13.8 (3.2)
242 11.9 (1.8)
343 15.6 (2.1)
488 22.6 (1.9)
716 17.2 (2.2)
Sweden
Iron mines
34
85 (smokers)
85 (nonsmokers)
7 (3.2)
22.3 (7.8)
16.3 (10.4)
Sweden
Lead and iron mines
240 28.4 (8.8)
390 35.0 (15.5)
Canadian uranium miners (Study 1)
21 3.8 (3.6)
72 9.6 (4.2)
180 11.1 (6.6)
Canadian uranium miners (Study 2)
15 (0-30) -7 (24)
46 (31-60) 4 (2.1)
76 (61-90) 12 (3.6)
106 (91-120) 5 (2.3)
150 (121-180) 12 (3.1)
Newfoundland fluorspar miners
204 18 (2.4)
1600 6 (0.8)
Excess risk/104 person-years
person-years (background)
- 1.9 (3.3)
14.4 (8.0)
23.4 (10.4)
37.4 (10.4)
19.4 (9.1)
52.8 (9.6)
77.3 (12.3)
210.0 (44.9)
3.3 (2.6)
13.9 (3.8)
24.0 (5.5)
28.8 (4.3)
53.5 (7.1)
110.3 (9.1)
123.2 (15.5)
2.4 (1.1)
19.0 (6.6)
13.9 (8.8)
68.2 (21)
136.5 (60.4)
8.0 (0.7)
6.9 (3.0)
20 (11.9)
-1.0
1.8
9.1
5.3
18.0
7.6
6.8
7.7
8.0
8.0
8.2
8.0
8.5
3.3
10.6
11.7
17.1
1.4
7.7
23
4
5
7
(3.6)
(1.0)
(2.7)
(2.4)
(4.6)
36.7 (4.9)
96 (13.5)
3.3
1.8
3.0
3.1
3.2
2.2
3.5
aNumbers in parentheses are approximate SE.
One analysis of the data on U.S. miners (98) shows
that excess risks from cigarette smoking and radiation
can be represented by a formula which is the product
oftwoterms, one linearinradiationexposure, the other
linear in cigarette consumption, so that much of the
difference in excess risks for different groups ofminers
may be due to differences in smoking habits. This is
confirmed by a reanalysis of grouped data for the Col-
orado miners (97). However, the risks from radiation
and smoking seem to be additive in the data from Hi-
roshima and Nagasaki (91), and some studies suggest a
protective effect of smoking at high radon exposure.
This last effect is attributed to the abnormally large
discharge ofmucus in the lungs ofheavy smokers: this
mucus absorbs the alpha radiation and so protects the
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gas in underground mines. Absolute excess risk (per 104 person
years) versus exposure (in working level months-see text).
300
0200
cn
BEST FIT OF
LOW DOSE GROUPS
2000 4000 6000 8000
WORKING LEVEL MONTHS
FIGURE 16. Lung cancer in U.S. uranium mines of the Colorado
Plateau Region. Excess risk (per 104 person years) versus expo-
sure (in working level months-see text).
mucus absorbs the alpha radiation and so protects the
surface cells. To complicate the interpretation of any of
the data, there may be other factors contributing to
lung cancer in miners. Fibrous materials akin to asbes-
tos, such as scarn and eummingtonite, are known to be
present in Swedish Zinkgruvan mines; and other prob-
able lung carcinogens, arsenic and nickel, are present
in the Czech mines (99). In the above analyses, no other
such factors have been incorporated.
An alternative way ofexaminingthe nonlinearity (90)
is shown in Figure 17, in which the excess risk divided
by the exposure is plotted against exposure (we have
added our estimates of statistical uncertainties). The
data on U.S. miners alone indicate that the excess can-
cer risk per cumulative WLM may be lower at high
doses than at intermediate doses. Excess lung cancer
risk per WLM is nearly the same for all U.S. miners
exposed to more than 500WLM, butis significantly less
(p<0.05) than excess risk per WLM for U.S. miners
exposed to 100 to 500 WLM. A decrease in excess risk
per WLM at high doses is also evident for two other
groups with exposures greater than 500 WLM: New-
foundland fluorspar miners and Czechoslovakian ura-
nium miners (Table 7).
In all groups, the lowest risk per WLM is that meas-
ured atlowest dose (below 100 WLM), andinmostcases
the value at the lowest doses is significantly lower than
the mean of the values at higher doses, corresponding
to upward curvature ofthe dose-response curves. This
curvature, though consistent, may be an artifact. In
most groups, cumulative exposure increased with age,
(as is evident on examining the last column ofTable 7),
sothat those exposed to higherdoses are observed later
inlife, whencancerhashad agreaterchanceto develop.
LEUKEMIA. Atomic Bomb Survivors. The Naga-
saki and Hiroshima atomic bomb explosions emitted
both low-LET gammaradiation and high-LET fast neu-
tronradiation. Accordingtoradiometrictheory, theleu-
kemia incidence in the irradiated survivors should be
described by a linear-quadratic dose-response formula
(with the quadratic term coming from the gamma com-
ponent ofthe radiation). It was originally thought that
the neutron component of the dose was substantially
higher at Hiroshima than at Nagasaki, in which case
tumor incidence data from Nagasaki should have been
more nonlinear with dose than similar data from Hi-
roshima. Originally this appeared to be the case (100),
but later analysis usingrecalculated doses (with amuch
reduced difference in neutron component) shows the
dose-response curves for the Hiroshima and Nagasaki
data to be nearly identical (101).
The BEIR III Committee (71) tried fitting three for-
mulae-the "LQ-L" formula, which contained both lin-
ear and quadratic terms for gamma dose and only a
linear term for the neutron dose; the "L-L" formula,
with only linear terms for the two types of radiation;
and the "Q-L" formula, which has a purely quadratic
term for gamma dose and a purely linear term for neu-
trondose. Although thenonlinearformulae describe the
Japanese leukemia experience adequately (L-Q:
X1i = 10.4, p = 0.49; Q-L: X22 = 12.3, p = 0.42), they
provide no better fit than the linear model (L-L:
X12 = 11.5, p = 0.49). The subsequent dose recalcula-
tionsat Livermore NationalLaboratory(101)alsoresult
in dose-response curves consistent with linearity (Fig.
18). The most recent cumulative statistics in the Na-
gasaki Tumor Registry, together with the new dose
calculations, lead to dose-response curves which are fit
best by a pure quadratic formula (102), although the
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quadraticterminalinear-quadraticfitisnotstatistically
significant.
The use oftotal leukemias as a measure ofresponse
in such dose-response curves, expecially for use in risk
assessments, has been criticized (72). Since the diverse
types of leukemias represent different diseases, each
may have substantially different dose-response char-
acteristics at low doses.
Childhood Leukemia. Childhood leukemias have
been associated with in utero X-ray exposures (103). A
dose-response curve with estimated uncertainties for
each data point (104) is shown in Figure 19. A linear fit
to this is as good as any could be, and better than a
quadratic curve, although that also is consistent.
BONE. Significant increases in osteosarcomas have
been inducedby exposure tohigh doses ofbone-seeking
3.5
+ Some exposure
but no record /
3.0 /
z/ w
30 NCRP dose limit / aio /X
1 o
w
> 1.5
-J~~~~~~~~~~~~~~~~~~~~~~~4
w
cE l
X-RAY DOSE (mrad)
FIGURE 19. Childhood leukemias resulting from in utero X-ray ex-
posures (103).
282DOSE-RESPONSE RELATIONSHIPS FOR CARCINOGENS
radium isotopes (Ra-224, -226, and -228) deposited in-
ternally, and by high doses of therapeutic X-rays. No
increase in bone cancers was seen amongJapanese sur-
vivors of the atomic bomb: five cases have been ob-
served in those within 1400 meters of ground zero,
where 4.67 cases would be expected. The incidence of
osteosarcoma at high doses of high-LET radiation ap-
pears to be a superlinear function ofthe dose rate.
Intravenous Injection of Radium 224. The most
precise information is for Germans intravenously
treated with radium 224 (half-life 3.64 days) for anky-
losing spondylitis or tuberculosis. The dose rate may
have been important: a single injection leading to 1 rad
average skeletal dose corresponded to a lifetime risk of
osteosarcoma of4 x 10-5, whereas injections over sev-
eral years leading to the same 1 rad average skeletal
dose corresponded to a lifetime risk of2 x 10-4 (105).
When dose rates are constant over a long period, a
comparison of cumulative dose with incidence can pro-
vide some insight on the differential effectiveness (in-
cidence/rad) of the radiation at low versus high doses,
but such a comparison for discontinuous and short ex-
posures can be misleading. As an example, Figure 20
shows acomparison ofcumulative average skeletaldose
with osteosarcoma incidence for the German patients
treated with radium 224.
Fittinganexponentialpolynomialformulatothisdata
suggestsastrongupwardcurvature (thequadraticterm
is highly significant, p
- 0.001). A naive interpretation
of this nonlinearity-that low dose rates are less tu-
70
60
w
0 wz50
z
° 40:
0
0
4
c O0 30
w z
0
20-
10-
00 1000 2000 3000
AVERAGE SKELETAL DOSE (RADS)
FIGURE 20. Bone sarcoma incidence (105) in German patients
treated with 'Ra versus cumulative skeletal dose (in rads). The
shape of this curve is misleading-see text.
morigenic than high-depends on an assumption that
the exposure periods were roughly equivalent. Here,
the highest cumulative doses were the result of the
lowest dose rates, and so the interpretation could be
precisely the opposite. This is indicated on Figure 21
(104), which relates incidence per rad to the treatment
period to suggest that a given amount of radium was
most carcinogenic if given over a long period of time
(low dose rate). We also show in Figure 21 the dose
rates (rad/month) over the treatment period ofthe var-
ious exposed groups. However, a complete analysis
would require that the effects of cumulative dose and
period of exposure be simultaneously modeled, and it
is unclear what the outcome of such an analysis would
be (E. Pochin, personal communication).
Poisoning of Dial Painters with "6Ra and 2asRa.
Luminous paint containing radium was used for watch
dials. The painters ofthese dials licked the tips oftheir
brushestoformagoodpoint, ingestingsomeofthepaint
in the process. Most exposure was to radium 226 (half-
life 1600 years), with possible additional exposure in
some cases to radium 228 (half-life 5.8 years). Some of
the painters later developed bone sarcomas. The dose-
response relationship appears very nonlinear (Fig. 22).
At high doses, above 1000 rads, induction of sarcomas
can be represented by a nonlinear dose-response curve
(106)
Risk = 3.7 x 10i . D2 exp(-1.4 x 10-4 D)
(37)
where D is the dose in rads. Information on the shape
of the dose-response curve at low doses is equivocal.
Low Doses. DISAGREEMENTS ABOUT SUB- AND SU-
PERLINEARITY. It is generally considered conservative
toestimatetheriskofexposure tolowdosesofradiation
by a linear extrapolation from the Japanese bomb ex-
perience, but some challenge this view, claiming that
such risk estimates are grossly underestimated. This
controversy has been extensively reviewed (71,73), and
we merely summarize some of it here.
Mancuso, Stewart, and Kneale. Mancuso et al.
(107,108) reported that the experience of employees at
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FIGURE 21. Bone sarcoma incidence per 106 person-rad. The same
data as Fig. 20-see text.
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(88).
the Hanford Works in Richland, Washington, who were
exposed to highly fractionated low doses of radiation,
has been far different from that of the atomic bomb
survivors, who were exposed to an acute and relatively
large dose. They present evidence that the incidence of
some cancers at Hanford is an order of magnitude
greater than expected using conventional extrapola-
tions from the atomic bomb experience. Others (109-
111) have confirmed the findings of increased multiple
myelomas and pancreatic cancers, but the absence of
myeloid and lymphocytic leukemia, the cancers most
expected, and the low statistical power of the study are
good reasons for viewing the claims of greater than
expected effects with skepticism. A second follow-up
study (112) reported that the excess of pancreatic can-
cers was no longer statistically significant, but that
there was an excess of stomach cancers that approached
significance; as an aside it is noted that one of the pan-
creatic cancers is likely to have been a stomach cancer.
The number of independent statistical tests of different
cancer categories in these studies makes it quite likely
that, simply by chance, one such category will appear
to have a statistically significant excess of tumors.
Bross et al. Unconventional statistical techniques
were applied to the Tri-state Leukemia Survey to show
that exposures in the 1-rad range from diagnostic X-
rays resulted in risks significantly larger than would be
"expected from the linear extrapolation procedures
used in the BEIR report," which "disregards subgroups
in the general population that are particularly vulner-
able to x-rays" (113). These conclusions have been
strongly criticized (71,114) on the grounds that they rely
on highly biased and arbitrary statistical techniques,
and also because of the casual treatment of exposure
data.
Cohen-Sublinearity at Low Doses. Cohen has com-
pared measured rates of cancer incidence with those
predicted for environmental radiation exposures using
the dose-responserelationships developed bythe BEIR
committees.
The BEIR I estimates (89) imply that environmental
radon causes at least 80% of all lung cancers in female
nonsmokers, while for the age group 24 to 44, at least
44% more lung cancers should be observed (115). Ifthe
histology ofthe tumors observed is taken into account,
the BEIR I estimates appear more at variance with
observation. Sixty-nine percent oflung cancers in min-
ers exposed to radon gas are ofthe small cell undiffer-
entiated type, while only 4% oflung cancers in the gen-
eral nonsmoking population are of this type, so that
overpredictions could be at least as large a factor of20.
Cancer rates in underdeveloped countries and early in
this century in the U.S. are used to further strengthen
this case. The estimates given in the later BEIR Com-
mitteereport(71)areclaimedtooverpredictlungcancer
risk in nonsmokers from background radiation by at
least a factor of40 (116).
Some members ofthe 1980 BEIR Committee argued
that the dose-response relation for radiation-induced
leukemia was superlinear; specifically, that risk at low
doses is proportional to the square root of the dose.
However, such a dose-response relationship would pre-
dict higher leukemia rates than those observed in the
various U.S. states between 1925 and 1933 for ages 25
to 34 (115).
AREAS OF HIGH BACKGROUND RADIATION. Most
evidence for nonlinearity ofradiation dose-response re-
lationships has been produced in occupational settings,
where exposures and risks are large and uncertain, or
from therapeutic exposures which are also large but of
short duration. The observed dose-response data cor-
respond to lifetime risks of 1% or more, so that any
nonlinearity observed in these studies must be consid-
ered high dose nonlinearity. For protection ofthe pub-
lic, it is the behavior of the dose-response relationship
at low doses which is of greatest interest. In practice,
small excess lifetime risks (below 1%), which may be
causedbysmallexposures, cannotbedeterminedunless
the background rates ofthe cancerunderstudy are also
very low, and a comparable control population is avail-
able.
Of special interest, therefore, are populations living
in areas of naturally high radiation levels but where
background exposures to man-made carcinogens are
low. The primary sources of elevated background ra-
diation are radon (radon-222) and thoron (radon-220)
and their decay products, so that elevations in lung
cancer rates would be expected in high background
areas. The two gases mentioned are themselves mem-
bers of the decay chains of uranium and thorium, re-
spectively.
Populations satisfying the required criteria can still
be found in rural areas ofless developed countries. Two
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have been carefully studied: those exposed to the mon-
azite deposits in Kerala, India, where most of the ra-
dioactivity (95%) arises from thorium decay products;
(117) and residents in the Dong-anling and Tongyou
regions of Yangjing County, Guangdong Province,
China, where bothuraniumandthoriumdecayproducts
yield relatively high radiation rates. Neither of these
populations has been shown to be at any increased risk
for lung cancer.
Pochin(118)hasdiscussedthestatisticalandtechnical
difficulties in studying these ideal populations. Even if
the highly exposed and control populations are well de-
fined and stable, observations on extraordinarily large
populations are required to discern small differences in
malignancyrates. These studies are extremely valuable
even if significant excess risks are not observed, for
they provide upper bounds on such excess risks at low
doses. Such upper bounds can be compared with the
effects observed at higher doses, for example, to test
whether there must be some nonlinearity in the dose-
response relationship.
In Yangjing, smoking among women is unusual and
amongmenitislow, andexposuretoindustrialpollution
is negligible. The background of lung cancers should
therefore be low, and if radon and thoron are causing
lung cancer here, their effect may be detectable.
The exposed andcontrolpopulation, alsofromGuang-
dong Province, have been carefully followed by the
Chinese High Background Radiation Research Group
(119,120), which keeps health statistics and makes ra-
diation measurements. Unfortunately, the control and
exposed populations are not exactly comparable. The
age distributions appear to be changing (De-chang Wu,
personal communication), and while 90% ofthe families
ofthe highly exposed have lived in the area for over six
generations, the control population appears to be more
mobile.
A summary ofradiation backgrounds in shown in Ta-
ble 8 (121), and from these it is estimated that exposure
rates from radon daughters alone are 0.26 and 0.12
WLM/year, and total exposure rates are 0.38 and 0.16
WLM/year, in the high and low background areas, re-
spectively.
In the high background area there were 23 lung can-
cer deaths in 764,696 person years ofobservation com-
paredto27deaths in777,482personyears inthe control
area. Adjustments for age and sex lead to lung cancer
mortality rates of 2.7 per 105 in the high background
Table 8. Background radiation in Guangdong Province, China
(121).
High background Control area
Radiation type/source area (mWL) (mWL)
Radon progeny
Indoor 5.2 2.2
Outdoor 4.7 2.5
Thoron progeny
Indoor 11.7 3.9
Outdoor 2.8 1.3
areaand 2.9 per 105 in the control area (121). An excess
exposure to 0.14 WLM/year of radon daughters thus
has not produced a detectable increase in lung cancer
mortality.
The expected increase in lung cancer mortality for
such an increase in exposure canbe computed usingthe
BEIR III (71) analysis. This calculation yields an ex-
pected 2.9 cases/year excess (the study period was 14
years) in the high exposure population, significantly
higher than the observed result. However, such a cal-
culation requires the assumption that the effects ofcig-
arette smoking and radiation exposure on cancer mor-
tality are additive. Making the alternative assumption
that the effects are multiplicative, the expected excess
risk per unit radiation exposure would be increased by
50% for smokers, and decreased by a factor of six for
nonsmokers. Withthisassumption, theexpected excess
cancer mortality would be 0.48 cases/year, not signifi-
cantly different from that observed.
Whittemore and McMillan (98) have reanalyzed the
data on lung cancer in U.S. uranium miners in order to
elucidatetheinteractionbetweencigaretteconsumption
and radiation exposures. They find that multiplicative
effects dominate; all the additive risk formulae tried fit
the data significantly worse (p <0.01) than the multi-
plicative formulae. The formula
Relative Risk =
(1 + 0.0031 * WLM)(1 + 0.00051 * PACKS)
(38)
described the data well, where WLM is the total cu-
mulative radiation exposure in working level months
and PACKS is the total cigarette consumption 10 years
prior to the time an individual was observed. The more
recent analysis of a more limited set of this data (97)
supports such a mixed (additive and multiplicative) for-
mula.
Thismultiplicativeformulaindicatesthatexcessrisks
for nonsmokers are much smaller than would be ob-
tained from the BEIR II estimates. We may use it to
estimate the excess cancer mortality expected in the
Guangdong Province study described previously. Since
smoking habits in control and highly exposed popula-
tions are said to be the same, we ignore the second
factor in the above equation. To obtain a worse case
estimate, assume an exposure of0.22 WLM/year for 65
years, which yields a relative risk of 1.042. Thus, an
excess of0.08 cases/year, or one case over the 14 years
of the study, would be expected. Since the standard
error is approximately 5 cases, the lung cancers ob-
served for control and highly exposed populations are
consistent with the U.S. uranium miner data as ana-
lyzed by Whittemore and McMillan.
ENVIRONMENTAL RADON AND LUNG CANCER IN THE
UNITED STATES. Using radon exposure calculated
from levels in U.S. buildings, Cohen (116) predicts lung
cancers due to radon using the BEIR III formula, and
finds them a factor of 40 too high. He attributes most
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of this difference (a factor of 10) to deficiencies in the
BEIR III analysis, buttherest (afactorof4)topossible
nonlinearity in the dose-response relation.
CHROMOSOME DAMAGE AT Low DOSES. Chromo-
some damage in blood lymphocytes ofnuclear dockyard
workers have been studied by Evans et al. (122). Ex-
posure wastomixedgammaand neutronradiation, usu-
ally below 5rems/year. There was asignificant increase
incertaintypesofchromosomedamage. Afteradjusting
forworker's age and time ofsampling, this damage was
shown to be consistent with a linear relationship of ef-
fect with cumulative dose.
Radiation-Summary. Table 9 is a summary ofthe
foregoing information. Simple theories ofradiation car-
cinogenesis suggest that the dose-response relationship
for radiation should depend on target site and radiation
quality. High doses of high LET radiation should give
a superlinear dose-response curve, and low doses oflow
LET a sublinear curve. Human data are mostly con-
sistent with these expectations, but they do not rule
out otherpossibilities. Most ofthe low LETdataappear
consistent with linearity (breast, thyroid, and leukemia
from X-rays), although a recent reanalysis of the leu-
kemia incidence arising from the atomic bomb radiation
suggests a purely quadratic curve (102). For high LET
radiation, the apparent shape ofthe curve may depend
on the quality of the data. At high doses the dose-re-
sponse curve is superlinear for bone cancers in the dial
painters and the ankylosingspondylitis victims exposed
to 224Ra, but at low doses the data is equivocal. There
is some evidence of sublinearity in the dose-response
curve for miners exposed to high LET radiation from
radon daughters, but here it is unclear whether age,
time, and smoking effects are completely taken into
account.
Exposure to Ambient Vinyl Chloride
Humanliverangiosarcomais averyraretumorwhich
has been associated with exposure tojust a few agents:
arsenic, vinyl chloride, and thorium dioxide (Thoro-
trast). The rarity ofthe disease is such that when even
only a few cases occur in the same location, exposure
to one of these agents is strongly suspected.
Over the past 30 years, 125 known angiosarcomas
cases have been produced among those occupationally
exposed in plants using vinyl chloride monomer. There
is substantial clustering in these data, with up to six
cases occurring in some plants and none or only one in
others. This suggests that a detailed study of the past
working conditions in these plants could allow estima-
tion of exposures, and hence give information on the
dose-response relationship. However, problems oflegal
liability make individual companies unwilling to release
such data voluntarily (R. Adams, personal communi-
cation).
The geographical distribution of angiosarcoma cases
in nonoccupationally exposed populations can be used
to infer some information about the dose-response re-
lationship. Brady et al. (123) report on all residents in
Table 9. Dose-response curves for radiation induced human
cancers.a.b
Cancer site Curve
Breast (A-bomb survivors,
fluoroscopy, X-ray)
Thyroid (bomb fallout, medical
treatments)
Lung (underground miners,
radon gas, for a particles
expect low dose linearity and
superlinearity at high doses)
Lung (atomic bomb)
Lung (Guangdong, China, an
area with high radon
background)
Bone (radium, expect low dose
linearity, high dose
sublinearity)
Childhood leukemia
(in utero X-ray)
All leukemias (atomic bomb)
Leukemia,Tri-state study
(NY, MD, and MN, mostly
exposure to X-rays)
Esophagus, stomach, intestine
and rectum, liver, pancreas,
lymphatic system, kidney,
bladder, brain, skin
All cancers except leukemia
(atomic bomb survivors)
Major sites except leukemia and
bone (atomic bomb survivors)
All cancers (Nagasaki)
All cancers (Hanford plant:
occupational exposures)
Linear to high doses; at high
doses some evidence of a
downward turn, possibly due
to cell killing
Possibly linear; further study
required
Individual studies consistent with
linearity assumption; quadratic
term in some studies
statistically significant; some
cases of significant downward
curvature at high doses
Linear and quadratic models fit
equally well
Equivocal when compared with
high dose data on miners
Superlinear at high doses;
equivocal results for low doses
Linear
Analyses differ over whether
linear or quadratic. Most
recent gives quadratic
A claim (113) that risks at low
doses are higher than would be
expected from the Japanese
experience is not generally
accepted
Data on dose-response very
limited or nonexistent
Cannot discriminate between
linear and quadratic, although
linear fits best
Cannot discriminate between
linear and quadratic
Upward curvature (92)c, linear
model best (102) when
leukemias are excluded from
the analysis
Superlinearity claimed (107), but
the claim strongly criticized,
and refuted by follow-up (112)
aUnless otherwise noted, information from BEIR Committee
Reports I and III (70,88).
bLinearimplies that cancer risk, R, is proportional to the dose D:
R X D; quadratic implies that R x D + c D2, where c is constant.
CAt a median dose of 120 rads, Kohn and Fry calculate a risk per
rad of 4 x 10-4/rad; at a median dose of 35 rads they estimate a
risk per rad of 1.3 x 10-4/rad.
New York State (excluding New York City) diagnosed
as having liver angiosarcoma from 1970 through 1975
and reported to the state's tumor registry. Each case's
proximity to a vinyl chloride or polyvinyl chloride man-
ufacturing facility was ascertained, as shown in Table
10.
From the New York State statistics, we calculate an
incidence of16 cases/6 years/10.68 millionpeople = 0.25
cases per million per year, nearly twice the national
annual incidence of 0.14 cases/million. However, ex-
cludingthosewithknownexposuretoAs, ThO2, orvinyl
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Table 10. Cases of angiosarcoma related to proximity of victims
to a vinyl chloride or polyvinylchloride plant.
Proximity to plant No. cases of angiosarcoma
In plant (worker) 1 (male)
Near plant (< 1 mile) 4 (females)
Away from plant: 2 (1 male and 1 female)
exposed to As and ThO2
No knowledge of exposure to 9 (3 females and 6 males)
As, ThO2 or VC
chloride (including those living near plants using vinyl
chloride) gives a rate equal to the national average.
There were four cases near vinyl chloride plants,
wheretheairconcentrationsofvinylchloridewerequite
low. This incidence can be compared with what would
be expected on the basis ofdose-response relationships
obtained by fitting various formulae to animal and oc-
cupationaldata. KuzmackandMcGaughy(124) assumed
alineardose-responserelationship andusedhumandata
to estimate that a lifetime risk of 0.13 corresponds to
20 ppm lifetime exposure to vinyl chloride, implying a
potency of 0.007/ppm. The National Academy of Sci-
ences (125) alsoassumed linearity and used humandata,
but obtained a potency of 0.0002/ppm. This analysis,
however, used earlierdataon angiosarcomas, andthere
is also reason to believe that the average exposure was
overestimated. The Food Safety Council (8) used Mal-
toni'sdataforangiosarcomainductioninratstoestimate
risks at low doses of vinyl chloride by assuming that
the dose-response relationship could be represented by
a gamma multihit formula, specifically (see also Fig. 5):
Risk = 7.2 x 10-3 x dose0.41 (39)
Population distributions near vinyl chloride plants
and the distribution of exposure to vinyl chloride have
been estimated (124). Approximately 50,000 New York
residents live within a 1 mile radius of vinyl chloride
plants and were exposed to approximately 0.5 ppm of
vinyl chloride, on average, before emissions were con-
trolled in about 1975. Before the effect ofvinyl chloride
on angiosarcoma incidence was identified in about 1973,
few attempts were made to have a tight system, and
typically, 5%ofallvinylchlorideprocessed wasreleased
as fugitive emissions. After control, the emissions were
negligible for our calculation purposes. The plants did
not begin operating until about 1955, so that lifetime
average exposure is approximately 0.5 ppm x 20/70, or
0.14 ppm. The number of cases expected is shown in
Table 11.
As may be seen, either ofthe formulae proposed for
the dose-response relationship could agree withthefour
cases ofangiosarcoma seen in the population near vinyl
chloride plants. If Kuzmack and McGaughy's interpre-
tation of the vinyl chloride occupational exposure data
is the most accurate, their linear formula is the better
predictor; on the other hand, ifthe NAS interpretation
is correct, the gamma multihit formula is the better
predictor, in spite of the peculiarities of its biological
interpretation.
Table 11. Predicted number of angiosarcomas cases caused by 20
years of exposure to 0.5 ppm ambient vinyl chloride.
Risk fonnula Cases
Model type (dose in ppm) Reference expected
Linear 0.007 x dose (124) 4.3
Linear 0.0002 x dose (125) 0.1
Gamma multhihit:
Human data 0.038 x dose041 (8,124) 72.9
Human data 0.0008 x dose04' (8,125) 1.5
Animal data 0.007 x dose04' (8) 13.4
Table 12. Bladder cancers in 78 men occupationally exposed to
P-napthylamine and benzidine at least 30 years after the time
of first exposure (127).
Length of exposure, Number ofmen % with tumors (life
years with tumors table corrected)
<1 3 9
1-<2 1 17
2-<3 3 48
3-<4 3 70
4-<5 8 80
--- 5 17 94
An additional epidemiological study was performed
by Mason (126) who compared cancer mortalities in
counties with plastics fabrication and manufacturing fa-
cilities with those counties without such facilities. He
was unable to distinguish the rare liver angiosarcomas
from other liver cancers, so his study has little sensi-
tivity and cannot be used in the same way.
Bladder Cancers Induced by f3-
Napthylamine
The primary aromatic amines f-napthylamine and
benzidine have long been known to induce bladder can-
cers in occupationally exposed men. Despite the many
case reports, there is little information on the dose-
response relationship. The best available information is
still the study byWilliams (127), whotraced the history
of78 men exposed to P-napthylamine and benzidine un-
der poorworking conditions. He cautioned that a "dirty
worker may absorb 20 times the dose of a clean one
under identical working conditions," but considered
length of exposure the only practical estimate ofdose,
and gave statistics on exposure and tumor incidence for
the 78 men. These are given in Table 12, and plotted in
Figure 23 (127-129). In Figure 23 we have added,ap-
proximate uncertainty estimates, which were not given
inthe original. Fittingpolynomialformulaetothis dose-
response curve indicates that there is some departure
from linearity; a quadratic formula is a better fit than
a linear formula, for example (p = 0.02).
Aflatoxin
The dose-response relationship for aflatoxin provides
an example of how a simple use of mathematical for-
mulae can be misleading. A frequently used procedure
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FIGURE 23. Incidence of urinary bladder cancers in 78 distillers of
,B-naphthylamine and benzidine (127). Error bars represent ap-
proximately one SD. The solid lines are (exponential) linear and
quadratic best fits.
for estimating this do8e-response relationship has been
to compare the incidence ofprimary liver cancer in var-
ious geographical regions with the logarithm ofthe av-
erage daily afiatoxin consumption in the same regions
(130-133). A straight line on this logarithmic plot fits
the data well (Fig. 24), suggesting that incidence is
linear in the logarithm of dose of aflatoxin. A Mantel-
Bryan formula also fits this data well.
However, theroleplayedbyaflatoxininthecausation
of human cancers is unclear. The incidence of primary
liver cancer (PLC) varies substantially from place to
place, from aslow as0.4%ofall cancersin someWestern
countries to as high as 65% ofall cancers in some areas
in underdeveloped countries. It had been thought that
exposure to afiatoxin B1, a potent liver carcinogen in
animals, could explain these geographical differences
(130,131); butit now seemsthatotherfactorshave some
role (134). Indeed, hepatitis B virus (HBV) appears to
have a causal connection with most liver cancers (135-
138). Aflatoxin exposureresultsindepressionofcellular
immunity (139), allowing persistent hepatitis infection;
further, afiatoxin more readily accumulates in livers
damaged by HBVinfection. The effects ofaflatoxin and
HBV might therefore be synergistic.
Enwonwu (140) argues that schistosomiasis is impor-
tant in the etiology ofPLC, although this can be ques-
tioned (141) by the strength ofthe association between
HBV and PLC where schistosomiasis is absent, and the
strength ofthe association between schistosomiasis in-
fection and previous infection with HBV. It is possible
that the effects of afiatoxin exposure are enhanced by
proteinmalnutrition(140), forsuchmalnutritionimpairs
30
LU
a
w
20
10
0
10 100
AFLATOXIN Bi INOESTED (ngAkg bw)
FIGURE 24. Incidence of primary liver cancer versus aflatoxin ex-
posure (13S). Incidence is per lo' per year. Note the logarithmic
dose scale. No other factors are taken into account-see text.
the activityofthe liver'smixed-function oxidase system
and somightallowaccumulationofaflatoxinintheliver.
Subsequent liver regeneration when high protein foods
become available would result in DNA replication, in
which processaflatoxin-induced mutationscouldbecome
fixed in daughter cells. Alcohol consumption is associ-
ated with PLC in Western countries, where most pri-
maryliver cancers are found in alcoholicswith ahistory
of alcoholic disease (135,136), but this association may
arise because of the presence of HBV in those with
alcoholic liver disease (136,137).
It is unlikely that HBV is the sole cause ofliver can-
cer. Such a hypothesis fails to explain why incidence of
PLC is always substantially higher among males than
among females in a given area or why rural and urban
areasofGreece(withthe sameprevalence ofHBV)have
substantial differences in the incidence of PLC (142).
In the Murang district ofKenya, PLC incidence varies
substantially between communities at high and low al-
titudes, yet HBV prevalence remains roughly constant
(143). In this case differences in aflatoxin exposure may
account for much of the geographical variation in PLC
incidence.
Data from this region (144) may thus provide a dose-
response relation between aflatoxin exposure and PLC
(Fig. 25), with less chance of being affected by the ef-
fects ofHBV. Formales, thedose-responserelationship
is consistent with a linear hypothesis; the best fit for
the female groups includes a quadratic term, although
it is not statistically significant (p = 0.14).
Thereisinformation onaflatoxin intake and liver can-
cer incidence for other countries, but the variation in
prevalence of HBV infection is generally not known.
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Dose-response modeling in such cases would be ex-
pected to yield variable and inconsistent results, and
this is what is observed. Data from some countries ap-
pears consistent with that from Kenya, while datafrom
other countries yield contradictory results.
Peers et al. (145) have expanded on earlier work
(146,147) to obtain aflatoxin exposure and liver cancer
incidence data for different regions in Swaziland. This
is in qualitative agreement with the Kenya data (Fig.
25): the dose-response relationship for males is linear;
for females, nonlinear, but not significantly so
(p = 0.375). Alpert et al. (148) studied Uganda; their
data is somewhat nonlinear (downward curvature), but
exposure information is uncertain. Bulatao-Jayme et al.
(149,150) report onprimarylivercancerincidenceinthe
Philippines as a function ofaflatoxin intake and alcohol
consumption, which both appeartobe highly correlated
with PLC. Unfortunately, their presentation of data
does not allow for dose-response modeling. Data from
Songkhla and Ratburi Thailand support the hypothesis
that aflatoxin and PLC are related (151-153), but is too
limited for dose-response modeling.
Stoloff (133) claims that aflatoxin consumption has
little correlation with primary liver cancer in the U.S.
He compared liver cancer incidence for different areas
ofthe United States with aflatoxin consumption. High-
est past consumption ofaflatoxin occurred inthe South-
east because oflarge concentrations in corn, the staple
starch there. However, there Was no significant ele-
vation in incidence of liver cancers in that region. The
study did not take into account alcohol consumption or
HBV infection prevalence. Stoloffcompares the North
and West to the Southeast, which has a substantially
lower rate of alcoholism (154). It is interesting to note
that application of the dose-response relation found in
Kenya to aflatoxin consumption in the U.S. predicts
many more liver cancers than are observed. The dif-
ference is presumably due to differences in HBV infec-
tion prevalence, in alcoholism, in other (unidentified)
environmental factors, or to some difference in popu-
lation susceptibility.
Animal Studies
High Dose Experiments of Relatively
Small Size
There have been many animal experiments per-
formed in order to evaluate the carcinogenicity of var-
ious materials. Most of these have used relatively few
animals and few doses. Plotting the outcomes (for ex-
ample, the fraction ofanimals with tumors) against the
doses should give some information about the dose-re-
sponse relationship, but this information is generally
very limited by the statistical uncertainty inherent in
the smali experiment sizes. Further information may
be gleaned by examining a large set of experiments
simultaneously, or by examining several relatively
small experiments performed on a single material. Nat-
urally, the best way to obtain information on the dose-
response relation is to perform large experiments de-
signed for this purpose.
NTP/NCIExperiments. The Carcinogenesis Bioas-
say Database System (155) is a computerized database
containing details of carcinogenesis bioassays per-
formed for the National Cancer Institute and National
Toxicology Program. Bailar et al. (156) have analyzed
consistently all the bioassays recorded in this database
(byJuly 1985, approximately 300 chemicals) for consis-
tencywithlineardose-response curvesatthehighdoses
used. Each experiment is too small to individually pro-
vide reliable evidence of consistency, but when all out-
comes (different tumor sites and types) are taken to-
gether it is possible to discern whether the whole set
isconsistent. Theyfindthatthedistributionofoutcomes
differs significantly from what would be expected ifall
materials acted linearly at each site for every tumor
type, with an excess of both sublinear and superlinear
behavior which persists even after correetion for com-
peting risks. This analysis can only show that for some
combinations of material, animal, and site and type of
tumor, sub-andsuperlinearresponsesoccur, butcannot
identify in which such combinations they occur. Fur-
thermore, the analysis does not deny the possibility of
linearity at lower doses than were used in the experi-
ments.
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Aflatoxin: Variable Results in Different Experi-
ments. Aflatoxin B1 is a potent carcinogen in animal
bioassays. At least one ofits metabolites binds directly
to DNA (157,158) (Fig. 8). This metabolite is thought
to be responsible for the strong biological activity of
aflatoxin (159), but mechanisms are not well enough
understood for the prediction of the shape of a dose-
response relationship. A linear relationship has been
experimentally found between applied dose and DNA
adduct formation. However, as discussed previously, it
does not necessarily follow that the dose-response re-
lationship between initiation and applied dose is linear.
Variation with dose ofthe site ofaction and the extent
ofrepair, either ofwhich would lead to anonlinear dose-
response relation, are currently under investigation
(160,161), (Irvin, personal communication).
Figure 26 and Table 13 present some ofthe best data
available for estimating the dose-response relation. In
one experiment (162) the results were significantly non-
linear (p <0.01), while in the remaining three (163-165)
linear relationships fit well. The potency of aflatoxin
apparently differs substantially between different
strains of rat, although some of this variation may be
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FIGURE 26. Dose-response curves for aflatoxin in three rat studies.
(A)data from (163); (B)data from (162); (C)data from (164). Av-
erage dose computed using Eq. 22-see text.
due to the strong influence of diet on aflatoxin liver
carcinogenesis (166).
In two of the experiments shown, the dosing sched-
ules fordifferent animals were varied, requiring a more
complicated treatment. We used Equation 22 to model
the age dependence of tumor induction and simultane-
ously account for the dosing schedules, allowing a test
as towhetherthe observedresults were consistentwith
alinearrelationbetween doseand tumorinductionrate.
With this assumption, the maximum likelihood estimate
for r and s in Equation 22 can be obtained. r may be
interpreted as the total number of stages in the carcin-
ogenesis process and s the stage affected by the carcin-
ogen, although this is an oversimplification. We prefer
to think in terms of fitting formulae that give some
information on the time dependence.
For the Barnes and Butler experiment the maximum
likelihood estimate for r is 4, and for s is 2. This is
consistent with the Wogan and Newberne intubation
experiment. However, intheirfeedexperimentthebest
estimate for n was 7, and for rit was 3. Although these
results are not entirely consistent with one another,
they all indicate that aflatoxin B1 most strongly affects
the middle of the process and that incidence is propor-
tional to age to some fairly large power, i.e., p(t) t,
where k 4 or more. This could partly explain the ap-
parent large variation in the carcinogenic potency of
aflatoxin between the experiments in Table 13, for the
experiment in which aflatoxin appeared the weakest
(163) lasted only 1 yearwhile that by Wogan et al. (162)
lasted 2 years, and the Butler and Barnes experiment
(164) 86 weeks.
Althoughtheformulafittingdescribedhereis sugges-
tive of certain hypotheses (such as those mentioned in
thepreviousparagraph), there areotherswhich arejust
as consistent withthese experiments. Forexample, one
can use the same sort of model as the one that led to
Equation 22, but aliow two stages to be affected by the
carcinogen. Then there are several sets of parameter
estimates which are consistent with all these experi-
ments, but which might be interpreted differently.
Benzo[aJpyrene. There have been many carcino-
genesis bioassays on benzo[a]pyrene using different
species, strains, dose rates, and other experimental de-
tails. In anefforttodeterminehowmuchofthevariation
in observed effects could be simply explained by vari-
ations in a few experimental protocols (such as age and
period of dosing) Zeise and Crouch (38) analyzed those
experiments in which benzo[a]pyrene was administered
orally to mice. The approach was to use an extended
multistage formula(Eq. 22) toanalyze eachexperiment,
and compare the parameter estimates, interpreted as a
potency, a number of stages, and the stage affected.
They found that forestomach cancer is likely to involve
a small number ofstages (less than 4) and that the dose
rate versus response function may be nonlinear. The
potencies measured in the experiments varied substan-
tially, their distribution being lognormal with a stan-
dard deviation of -0.6 (base 10 logarithms). Some of
the variance could be explained by the variation with
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Table 13. Aflatoxin dose-response in rats: multiple dose group studies.
Study
Newberne (163): linear dose
response [p(d) = 1 - e"b'] fits
very well. Strain is CD unless
otherwise specified. Length of
study:
- 1 year.
Wogan et al. (162): (Male Fischer
rats) quadratic term statistically
significant (p) = 0.004)
Butler and Barnes (164): (Male
Porton Rats) consistent with a
linear model, but also with
nonlinear models. Length ofentire
study:86 weeks.
Aflatoxin content in diet
ppm
5.0
3.5
3.5
1.0
1.0
0.2
0.2
0.005
jig/kg
0
1
5
15
50
100
ppm
5.0 (0.005)d
5.0 (0.04)
5.0 (0.14)
5.0 (0.29)
0.5 (0.50)
0.1 (0.10)
Duration of
exposure, weeks
1
3
6
9
86
86
Liver tumor incidence
14/15
11/15
7/10"
5/9
8/15
2/10
1/lOb
0/1bC
Liver cell
carcinomas
0/18
2/22
1/22
4/21
20/25
28/28
Hepatocellular
carcinomas
0/13
3/20
12/19
6/6
25/25
17/34
0/46
ppm
Wogan and Newberne 1.0 (for 2 weeks)
(165) 1.0 (for 2 weeks)
1.0
1.0
1.0
1.0
1.0
1.0
0.3
0.3
0.3
0.3
0.015
0.015
0.015
0.015
0.015
Intubation
amount per treatment,
mg/kg
body weight
Number of
treatmentsf
5
5
5
5
5
1.0
1.0
0.5
0.5
0.5
mg/kg/day
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0.15
0.05
0.05
0.05
0.05
0.0025
0.0025
0.0025
0.0025
0.0025
1
1
1
1
1
S
S
10
10
10
Time ofsacrifice,
weeks Male
18 0/3
35 0/5
82 0/16
18 0/3
35 4/5
41 16/17
52
64
18 0/3
35 2/7
52 8/13
60-70
18 0/3
35 0/3
52 3/5
68 12/12
80
16
25
38
55
69
35
82
18
35
82
0/3
0/5
0/5
0/4
1/5
1/3
1/5
4/19
Female
0/3
0/7
1/13
0/3
0/5
0/7
1/3
4/4
0/3
0/5
0/5
11/11
0/3
0/5
0/3
13/13
0/4
2/16
0/3
0/3
6/17
'Holzman rat.
bOriginaly given (209) as 0/10.
cStrain not specified.
dIn parentheses, average daily dose, in ppm, calculated using Eq. 22 (38) assuming the second of four total stages was affected by the
carcinogen.
eFeeding over 1 day with meal contaminated with 1.0, 0.3, and 0.015 ppm aflatoxin corresponds to an exposure of approximately 0.15,
0.05 and 0.0025 mg/kg body weight.
'Given on consecutive days.
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dose rate, for on average, potencies were largest when
benzo[a]pyrene was given at high dose rates. The re-
sults ofthe large experiment by Neal and Rigdon (167)
areconsistentwiththisexplanationandindicateasharp
discontinuity in the dose rate versus response curve.
Both above andbelow (butnot across) the discontinuity
the results are consistent with a linear formula (Fig.
27). The slope corresponding to the higher dose rate is
an order of magnitude greater than the slope for the
low dose rate group. Thus, the dose rate versus re-
sponse relationship may be described by a hockey-stick
shaped function.
This relationship is consistent with some results for
DNA adduct formation (55), but not with others (168)
which show a linear relationship between benzo-
[a]pyrene dose and DNAadductformation inthemouse
forestomach. However, the results are also consistent
with the alternative hypothesis that benzo[a]pyrene af-
fects two stages in the process oftumor formation, an
early stage and a late stage, both in a linear fashion.
Large Experiments
Saccharin. When male rats are exposed to sodium
saccharin in utero and then dosed throughout their
lives, the dose response relationship forbladder tumors
is strongly nonlinear (Fig. 28 and Table 14). In most,
but not all, experiments in which rats were dosed con-
tinuouslythroughouttheirlife but notinutero, noblad-
dertumors were seen (169,170). Theresults oftwo gen-
eration bioassays are shown in Table 14. They give
consistentresults forthetwostrains, withthe Sprague-
Dawley rat more sensitive than the Charles River rat.
Many differrent mechanisms have been proposed to
explain the carcinogenic activity and dose-response
characteristics of saccharin, although some proposed
A High dose rategiven Low done
for o long time for a long
I | Standard error High dor s
for e sher
.. Lower to uppr bounds
1.0 - on(t/To)2 *df
0
0.8
' ~ BEST FITS
04- 15
4r1.1
mechanisms have been later ruled out. It was initially
thought that the tumors might be due to saccharin-
induced bladder stones, which would probably not be
formed atthe lowlevels ofhumanexposure. Thiswould
make saccharin a secondary carcinogen. However, the
presence ofmicrocalculi did not appearto be correlated
with the formation ofbladder tumors in any ofthe two
generation bioassays. Saccharin does not appear to be
metabolized in rats (169), even with concurrent expo-
sure to phenobarbitol or 3-methyl-cholanthrene. It also
does not bind to bladder or liver DNA in vivo and so is
notusuallyconsideredtobeacompletecarcinogen(171).
It may act as a promoter or cocarcinogen, although the
mechanism for any such action is not understood
(169,172). However, recent work shows that at very
high doses it can produce structural disturbances in eu-
karyoticchromosomes invitro and canbeaveryweakly
active germ-cell and somatic-cell mutagen invivo (173).
In addition, its administration following freeze ulcera-
tion, which induces regenerative hyperplasia, resulted
in bladder tumors in the absence ofa chemical initiator
(174).
The concentration of saccharin in various tissues of
male Charles River CD rats was studied by Sweatman
and Renwick (172). Saccharin was fed to the rats at 1
to 10%dietaryconcentration, atorbelowconcentrations
found to produce bladder tumors in earlier studies
(169,170,175-179). Table 15 and Figure 29 show their
results. The relationship between dietaryconcentration
and plasma, kidney, or bladder concentration is nonlin-
ear. Anincreaseintheslopesofboththetumorresponse
curve and the plasma saccharin concentration curve oc-
curs at roughly the same place (compare Figs. 28 and
29).
Concentrations in the urinary bladder and kidneys
appear to be greater than in the plasma, but these dif-
rotegiven
time
rotegiven
rt time
15I
0.1 0.2 0.3 0.4 0.5 0.6 0.7 1.4 2
CORRECTED DOSE RATE:(4 ) * df (in mg/kg-day)
FIGURE 27. Dose-response curvesforbenzo[a]pyrene-inducedforestomachtumorsinmice (38). Thedose-response curvesappeartobedifferent
for high dose rate and low dose rate groups. Eq. 22 was used on the data from a single experiment (167). Each number indicates a group
of mice with differing exposure-time proffles. e andfare the same as r and s, respectively, in Eq. 22, and dfis the multiplier of b in Eq.
22. Fore=2,f=1.
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FIGURE 28. Probability of bladder tumor in rats exposed to sac-
charn in their diet (i75).
3
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FIGURE 29. The concentration of saccharin in the tissues of male
rats which were fed saccharin in their diet (172).
Table 14. Sodium saccharin: bladder cancer in male rats exposed
in utero and throughout life.
Study
1973 FDA Study
(176,179),
Charles River CD
rats
Canadian Health
Protection Branch
(169), Sprague
Dawley rats
Wisconsin Alumni
Research
Foundation (178,179)
Sprague-Dawley
Rats
Animals with tumor/
Dose, (% in diet)' total number tested
0.0 1/25
0.01 0/16
0.10 0/27
1.0 0/22
5.0 1/2b
7.5 7/23b
0
5
0
0.05
0.5
5
0/42
12/45
0/12
0/10
1/12
8/15
Calorie Control 0 0/324
Council (175), 1 5/658
Charles River CD 3 8/472
rats 4 12/189
5 15/120
6.25 20/120
7.5 37/118
5% in diet ofanimals and their mothers.
bNumbers ofanimals with tumors may differ in other citations of
this study due to disagreements in pathological diagnosis oflesions.
Table 15. Tissue saccharin concentrations in male rats fed
1-10% saccharin in their diet (172).
Dietary level, Saccharin concentration in ,Ig/g or p.g/mLa
% Plasma Bladder Kidneys
1 29.6 ± 9.7 120.7 ± 129.3 101.6 ± 79.7
2 53.2 ± 10.7 51.6 ± 35.3 129.3 ± 36.1
3 69.9 ± 12.7 72.9 ± 29.3 201.1 ± 51.1
5 146.4 ± 42.8 118.8 ± 64.9 465.9 ± 108.8
7.5 266.6 ± 62.0 377.3 ± 235.4 1008.8 ± 367.8
10 418.0 ± 103.0 632.6 ± 441.6 1014.2 ± 392.6
'Plus or minus SE.
ferences arenotstatistieallysignificant. Concentrations
of saccharin in the bladder remain relatively constant
between 1 and5%dietaryintake, butmarkedlyincrease
athigherdietarylevels (7.5%and 10%). However, these
differences alone cannot explain the nonlinear dose-re-
sponse relationship for bladder tumors, since F1 males
are not unique in accumulating saccharin at high dose
levels. The same happens in females and Fo males and
neither ofthose experience bladdertumorrates as high
as F1 males (180).
One piece of evidence suggesting that saccharin is a
promoter in bladder tumorigenesis was its nonlinear
dose-response curve. If this nonlinearity is explained
simply as a result ofpharmacokinetic mechanisms, this
argument is valueless. It is possible that saccharin is a
promoterwith alineareffective dose (e.g., bladdercon-
centration) versus response relationship, but there is
evidence which suggests otherwise. Trosko (62) applied
his in vitro assay for interference with metabolic co-
operation to saccharin, and found a strongly nonlinear
response.
An alternative promoter mechanism has been pro-
posed (181,182). High dietary concentrations result in
enlargement of the cecum, producing an accumulation
ofprotein there, and changes in the composition ofthe
intestinal microflora. These changes have been associ-
ated with the production ofthree to fourtimes the nor-
mal quantities of substances known to have promoting
orcarcinogenic properties: indole, phenol, andp-cresol.
Indole is known to be a cocarcinogen for the urinary
bladder; furthermore, its renal clearance as indican is
inhibited by saccharin (183). Both p-cresol and phenol
have been used as promoters in skin carcinogenesis ex-
periments.
Greenfield, Ellwein, and Cohen (59) have compared
a two-stage model with the results of experiments on
bladder carcinogenesis in Fischer 344 rats exposed to
sodium saccharin (with or without prior exposure to
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FANFT, an initiator). They suggest its action is due to
increases in mitotic rates, and hence stem cell popula-
tions, but that it does not affect the rate ofinitiation or
transformation of cells.
There are thus several proposed mechanisms to ex-
plain the action and nonlinear dose-response relation-
ship of saccharin: that it acts as a promoter by inter-
fering with metabolic cooperation among cells; that it
acts as a promoter by increasing mitotic rates; that it
is weakly mutagenic and may cause initiation ifapplied
at a time when the bladder epithelium is rapidly pro-
liferating; that it exhibits nonlinear pharmacokinetics;
that it acts indirectly by inducing the production ofthe
promoters and cocarcinogens indole, phenol, and p-cre-
sol; and that it induces calculi which are somehow re-
lated to the formation ofbladdertumors. Which, ifany,
of these finally prove to be the major mechanism(s) of
action remains to be seen, but that so many different
mechanisms have fallen in and out offavor serves as an
indicator that we should proceed cautiously when as-
suming particular mechanisms.
Radiation. Various shapes of dose-response rela-
tionships are seen in experiments on animals in which
tumors are induced by radiation exposure. There are
upward curving (sublinear) dose-response relationships
forlowLETradiation [e.g., mammaryadenocarcinomas
and adenofibromas in rats (184), skin cancerin mice and
rats (185,186)]. In several studies theincidence ofmam-
mary cancer reaches a constant value, less than 100%,
athighdose(89). Thedose-response curveformammary
cancer in some strains of mice exposed to whole body
radiation is complicated, since theradiation alsoinduces
ovarian tumors which secrete estrogen and stimulate
growth of mammary tumors. There are also several
experiments inwhich tumorincidence decreases athigh
doses, an observation usually explained by supposing
that at high doses the radiation is killing cells which
would otherwise have given rise to tumors. Examples
include leukemia (187) and ovarian tumors (71) in mice.
Inadditiontototaldose, thedoserateisofimportance
in controlling the shape ofthe dose-response curve for
radiation induced tumors. These effects have been re-
viewed by Upton (72). The effectiveness of low LET
radiation in inducing leukemias appears to decrease as
thedoserateisreduced, possiblybecausesmallamounts
ofdamage can be repaired (71). The opposite effect has
been observed for (high LET) alpha radiation. At a
fixed, relatively high cumulative dose of intraperito-
neally injected Ra-224, reducing the dose rate can sig-
nificantlyincrease osteosarcomaincidence (Table 16and
Fig. 30).
Mulleret al. (188) suggest that this effect maybe due
to a reduction in cell loss rate at lower dose rate, to cell
proliferation (normal or stimulated by the radiation) in-
creasingthe number ofcells exposed, or to promotional
effects of radiation being enhanced by the increased
time ofaction at low dose rate. They argue against the
second possibilitybecausetheriskofosteosarcomadoes
not unduly increase when fractured tibiae are irradi-
ated.
Vinylchloride. Vinyl chloride is known to cause liver
angiosarcoma in rats, mice, and humans. In Sprague-
Dawley rats, the incidence of angiosarcoma increases
withexposureuntilaplateauisreached(Fig. 31);higher
exposures have no additional effect (189). A straight
line connecting the point at high dose to the origin
underestimates the observed low dose incidence, while
use of a gamma multihit formula for fitting the dose-
response relationship results in overestimates of low
doserisk. Thegammamultihitformulasuggestsatumor
risk proportional to the square root of dose (8).
As discussed in "The Pharmacokinetic Models," the
shape of this dose-response curve has been explained
by the pharmacokinetics of vinyl chloride and its me-
tabolites (47-52,190). Gehringet al. (51,52) used animal
data to estimate the relationship between the amount
of vinyl chloride entering the body and the amount of
active (carcinogenic) metabolite formed, that is an ef-
Table 16. Osteosarcomas in female mice after ID injections of "4Ra (188).
Single injection
No. ofmice
92
50
93
49
92
91
200
200
460
Injected activity,
,Ci/kg-body
weight
50
36
25
12
10
5
2.5
1.0
0
Protracted injection
49
50
50
50
100
1.5
0.5
4.5
1.5
0.5
12
12
36
36
36
Total dose, rad
1500
1080
750
360
300
150
75
3
0
,uCi/ injection
4
12
4
12
36
360
360
1080
1080
1080
Osteosarcoma
incidence,
fraction of
animals
0.14
0.08
0.11
0.22
0.15
0.15
0.10
0.07
0.01
Weeks of
treatment
0.39
0.46
0.22
0.62
0.92
SD
0.036
0.038
0.032
0.059
0.037
0.038
0.022
0.018
0.005
0.07
0.07
0.059
0.069
0.027
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o DOSE FRACTIONATED
( ) TREATMENT SPAN (Weeks)
i(36)
detailed multistage model (Eq. 23, with 3 stages). The
compartmentmodelwasusedtodeterminethequantity
of DNA adducts (taken to be the effective dose) for a
givenapplieddose. Figure32showstheaverageamount
ofDNA (nm DNA adducts/g DNA) bound after 30 min
exposure as a function of vinyl chloride concentration.
Ranking the organs by the amount ofbinding gives an
order similar to that obtained if they are ranked by
tumor response to vinyl chloride. Figure 33 shows the
observed response versus a measure of effective dose
in the liver, together with the shape ofcurve expected
from a multistage model with three stages.
Experiments with 2-AAF. In most animal experi-
ments the aim is to dose the animals at maximum tol-
erated doses (MTD), so that experiments are as sen-
sitive as possible to carcinogens. In such experiments,
0 200 400 600 800 1000 1200 1400 1600
CUMULATIVE DOSE (RADS)
FIGURE 30. Osteosarcomas induced in female mice injected IP with
'Ra.
FIGURE 32. Effectivedose totheliver(DNAadducts, innM/gDNA)
versus vinyl chloride exposure, predicted by a pharnacokinetic
compartment model (57).
FIGURE 31. Dose-response function for vinyl chloride exposure of
rats (189).
tabolites (47-52,190). Gehring et al. (51,52) used animal
data to estimate the relationship between the amount
of vinyl chloride entering the body and the amount of
active (carcinogenic) metabolite formed, that is an ef-
fective dose, and so obtain a dose-response relationship
using the effective dose. They then applied this dose-
response relationship to humans, using a scaling la-w
based on body surface area, to estimate effective doses
in humans.
The transport of exogeneous materials round the
body, and its metabolic activation, can be described by
physiologic compartment modelswhichinclude akinetic
description of the metabolic transformations occurring
in each body compartment. This has been attempted in
the case of vinyl chloride (58,191) with the additional
attempt at coupling this compartment model to a fairly
CANCER RISK (%)
4
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FIGURE 33. Risk ofliverangiosarcoma in rats exposed tovinylchlo-
ride versus the effective dose to the liver (57).
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effects that occur only at high doses may be observed.
Usually we are interested in human effects at much
smaller doses, far below those used in animal tests. It
is tempting to believe that a series ofvery large animal
experiments might help answer the question ofhow to
perform high to low dose extrapolations. The EDO1
study is such an experiment in which large groups of
mice were fed the carcinogen 2-acetylaminofluorene (2-
AAF) at several doses far below the MTD. A total of
24,193BALB/cfemalemicewereused. Severalanalyses
ofthe data have been performed (192-194).
In Figures 34 and 35 we show the probabilities of
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FIGURE 34. Bladder tumor incidence versus dose of2-AAF (193) in
female BALB/c mice.
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FIGURE 35. Liver tumor incidence versus dose of 2-AAF (193) in
female BALB/c mice.
tumor forbladder and livertumors observed in the sac-
rificed animals, togetherwith fitted lines corresponding
to polynomial formulae. The dose-response relationship
forthe normally rare bladdertumoris highly nonlinear,
while that forthe normally common livertumoris much
more linear. However, there is a small, statistically sig-
nificant, nonlinear component to the dose-response
curveforlivercancersinanimals sacrificedat24months
(p <0.00004).
Brown and Hoel (195,196) find fault with those anal-
yses that assume factorable hazard function (e.g., like
Eq. 26). They find liver cancer incidence to be a non-
linear function ofthe dose applied, but that the nature
ofthenonlinearitycanbeexplainedinatleasttwoways.
First, with a multistage formulation with a total of 4
stages, in which two stages are affected by the carcin-
ogen; second, againusingamultistageformulation, with
2-AAF affecting an early stage (e.g., possibly behaving
asaninitiator)butwithnonlinearityintroducedthrough
pharmacokinetic reactions at low doses.
N-diethyl- and N-dimethyl-nitrosamines. The
British Ministry of Agriculture, Fisheries and Food
commissioned a large animal bioassay, using over 4000
Colworth rats to characterize the dose-response rela-
tionship for cancers caused by N-diethylnitrosamine
(DEN) (esophagus and liver) and N-dimethylnitrosa-
mine(DMN) (liver). Thedatawasmeticulouslyanalyzed
by Peto et al. (197,198), who compared observed num-
bers ofanimals with tumors to numbers expected under
the hypothesis that the treatment had no effect on tu-
mor incidence (Tables 17 and 18).
They compactly summarized the datausinga formula
of the form
- log(l - p(t,d)) = b. (d+ a)ktm (40)
where p(d,t) is one minus the probability of an animal
being alive and free of a particular tumor after t years
oftreatment at an average daily dose d, in the absence
ofothercausesofdeathandothertumors. Thatis,p(d,t)
is a measure ofthe cumulative incidence in the absence
ofcompetingrisks. Theintegerexponents kand mwere
not formally estimated, but were chosen to give good
agreement with the data. The results of this detailed
analysis are shown in Table 19.
One can show that p(d,t) is approximately propor-
tional to the ratio ofthe observed to expected numbers
ofanimals with tumors. This ratio is plotted against the
concentration of DEN or DMN in the feed (which we
use as the measure of dose) in Figures 36, 37, and 38.
Superimposed upon the plots are polynomial curves of
the form
OBSERVED/EXPECTED =
xO+x1
- d+X2 .d2+***+x7 *d7
(41)
where each coefficient is forced to be non-negative. We
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fitted such curves to the data from differing numbers
of dose groups, and label them on Figures 36-38.
The strong nonlinearity seen for esophageal cancer
induced by DEN is reflected in the summaries in Table
19 where the estimates for "a," the background param-
eter, are zero. For both males and females, the curves
fittedtolowdose datadiverge strongly atlowdosefrom
those fitted to all data points (curves A and B, Fig. 36).
Response tolivertumorsdiffersinmalesandfemales,
despite the similarity ofthe summary statistics in Table
19. For males, all the fitted curves are similar at low
doses. For females, however, the increase in tumor re-
sponse as dose increases appears to be initially less
rapid. This is emphasized by the divergence of the
curves fitted to low dose data only, from those fitted to
all data points. Thus, although the dose response re-
lationship for DEN- and DMN-induced liver cancer ap-
pears to be linear at low doses in females as well as
males, the slope ofthe curve at low doses is not as well
predicted in the former case by high dose data.
That the response to rare esophageal cancers was
nonlinear at low doses (Fig. 36 and Table 17) came as
no surprise (197,198). The theoretical arguments of
"TimeandAge" suggestexactlysucharesultfortumors
with low background incidence, although it is possible
that a still larger experiment, in which background in-
cidence was just observable, one would find dose-re-
sponse characteristics more similar to that observed for
liver tumors in the female rats. At sufficiently low dose
rates, Peto et al. found the more common liver cancers
simply proportional to the dose rate; in addition, other
nonneoplastic lesions of the liver, such as hyperplastic
nodules, were present at low doses with an incidence
roughly proportional to the dose rate.
The Use of Dose-Response
Relationships
Uncertainty
The shape of dose-response relationships for cancer
at low doses is largely unknown because there are few
or no data and because there is no generally accepted
theory. Nonetheless, legitimate questions are contin-
ually asked by the public about the probable response
(the risk) at these doses. Any risk assessor who writes
down a value for risk is making ajudgment based upon
beliefanduponconstraints imposedbyposition, by stat-
ute, or otherwise.
Most discussions ofuncertainty in carcinogen risk as-
sessment avoid this uncertainty due to lack of under-
standing and concentrate on the statistical uncertainty
of a particular epidemiological study or bioassay.
Crouch and Wilson (199,200), and Gaylor and Chen
(201), emphasize the importance of including also the
uncertainty in interspecies comparisons, and Wilson et
al. (202) emphasize including the uncertainty about
whether or not a chemical is a human carcinogen. The
essence of risk is uncertainty. To ignore uncertainty,
therefore, is to incorrectly describe the risk. However,
the uncertainty about dose-response relationships is so
large that it is difficult to handle. Rather than being
sweptundertherug, itshouldtherefore beemphasized.
One way ofdoingthis is to perform allthemechanics,
the arithmetic of risk assessment, first, and leave the
uncertainty in dose-response relationship for last by
qualifying all results with an explanation ofthis uncer-
tainty. Performing such mechanics usually requires the
use ofsome formula to represent the dose-response re-
lationship, and so one should be chosen which is con-
sistent with available data and appropriate for the task
at hand. We mention below two such choices, which
include also an appropriate parameterization ofthe for-
mulae. This approach is valuable, for it may turn out
that this uncertainty is almost irrelevant, for example,
in trading offone risk against another. It may also turn
out to be more expensive to argue overthe shape ofthe
dose-response relationship than to reduce exposure so
that the risk is de minimis even with pessimistic as-
sumptions (e.g., assuming that a linear formula ade-
quately reflects the shape of the dose-response rela-
tionship). However, such a course of action must be
explicit, and only taken if it does not prejudice subse-
quent actions.
Best Estimate ofRisk. The National Cancer In-
stitute was requested by Congress to produce a set of
tables estimating the probability that an observed can-
cer was caused by a specified radiation dose. It was
decided (91) to use a linear-quadratic formula (a linear
formula was used for breast and thyroid) to represent
the dose-response relationship. The best estimate of
risk from the use of such a formula, and therefore the
best estimate for the probability of causation, is lower
than that which would have been obtained had a linear
formula been used.
It is too early to tell how this, or similar studies for
chemicals, might be used, for example, in legal pro-
ceedings. The tables, representing a consensus of the
opinions of members of an expert committee, might be
used for assigning liability. An expert witness would
then have the onus of proof to explain why the risk is
more or less than given by the tables. In some legal
situations, however, a best estimate ofrisk may not be
the parameter of concern; although the practice is
changing, the law has tended to accept only demon-
strated physical harm as a basis for action, and not a
risk estimate. Based on this past practice, therefore,
courts may regard these tables as too speculative. Con-
trariwise, the tables might be considered insufficiently
conservative for setting safety standards.
Upper Bound on Risk. Most risk assessments are
performed to assess whether a chemical can be widely
used or whether further precautions must be taken in
its use. This particularly applies to risk assessments by
the FDA, CPSC, and EPA. It is appropriate for this
application to chose a conservative representation for
the dose-response relationship (i.e., one that gives pes-
simistically large estimates of risk at the doses of in-
terest).
With this in mind, the FDA chose the Mantel-Bryan
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Table 17. Dose-response relationship for tumors causing death in DEN-treated rats (197).
DEN Male Female
concentration, ppm Expected Observedab Ratio Expected Observedab Ratio
Esophagus Mc + Bd NKe + Mc + Bd
0 58.0 0 + 0 0.0 16.7 0 + 0 0.0
0.033 15.0 0 + 0 0.0 4.1 0 + 0 0.0
0.066 15.8 0 + 0 0.0 4.3 0 + 0 0.0
0.132 15.4 0 + 0 0.0 4.2 0 + 0 0.0
0.264 13.6 0 + 0 0.0 4.4 0 + 0 0.0
0.528 15.5 0 + 0 0.0 4.1 0 + 1 0.2
1.056 14.5 3 + 5 0.6 4.1 1 + 3 1.0
1.584 14.0 9 + 4 0.9 3.6 3 + 0 0.8
2.112 10.5 21 + 5 2.5 3.4 1 + 10 +
le 3.5
2.640 10.0 21 + 6 2.7 2.6 1 + 0 0.4
3.168 8.8 24 + 5 3.3 2.1 4 + 2 2.9
4.224 6.4 12 + 6 2.8 1.5 5 + 1 3.9
5.280 4.9 16 + 7 4.7 1.3 9 + 2 8.5
6.336 3.8 15 + 7 5.9 0.9 5 + 3 8.5
8.448 2.4 20 + 8 11.7 0.6 2 + 1 4.8
16.896 0.6 9 + 7 25.7 0.1 3 + 0 21.2
Total (all doses) 210.0 150 + 60 1.0 58.0 1 + 43 + 14e 1.0
Liver
0 61.4 1 0.02 123.0 1 0.01
0.033 15.6 1 0.06 30.2 0 0.00
0.066 16.4 0 0.00 31.1 0 0.00
0.132 16.1 5 0.31 30.3 1 0.03
0.264 14.5 2 0.14 32.1 1 0.03
0.528 16.2 4 0.25 29.6 3 0.10
1.056 15.0 8 0.53 29.6 23 0.78
1.584 14.1 14 0.99 26.3 37 1.4
2.112 11.2 7 0.62 24.6 38 1.5
2.640 11.1 17 1.5 19.1 47 2.5
3.168 10.4 17 1.6 16.4 42 2.6
4.224 8.1 26 3.2 12.3 42 3.4
5.280 6.4 26 4.1 10.5 43 4.1
6.336 5.1 30 5.8 7.4 47 6.4
8.448 3.9 25 6.4 5.1 55 0.8
16.896 1.4 44 32.0 1.4 49 4.7
Total 227.0 227 1.0 429.0 429 1.0
aEach control group initially consisted of 240 animals.
bEach treatment group initially consisted of 60 animals, except females given 2.112 ppm, which began with 66 animals, and those given
16.896 ppm, which began with 54 animals.
cMalignant.
dBenign, no malignant present.
eNot known due to tissue loss.
Table 18. Dose-response relationship for liver tumors causing death in DMN-treated rats (197).
DMN Male Female
concentration, ppm Expected Observedab Ratio Expected Observedab Ratio
0 86.3 1 0.01 120.3 1 0.01
0.033 23.0 1 0.04 31.0 1 0.03
0.066 22.4 3 0.13 30.3 0 0.00
0.132 22.0 3 0.14 28.8 2 0.07
0.264 21.9 3 0.14 31.3 3 0.10
0.528 23.9 3 0.13 29.2 5 0.17
1.056 21.0 5 0.24 30.6 5 0.18
1.584 21.1 3 0.14 25.5 27 1.1
2.112 21.7 13 0.60 25.4 23 1.3
2.640 17.2 27 1.6 21.2 44 2.1
3.168 17.1 33 1.9 19.4 48 2.5
4.224 14.6 36 2.5 16.0 53 3.3
5.280 10.4 46 4.4 11.2 52 4.6
6.336 9.4 49 5.2 10.5 51 4.9
8.448 6.4 55 8.6 5.5 55 10.0
16.896 1.7 59 34.5 1.9 58 30.8
Total (all doses) 340.0 340 1.0 438.0 438 1.0
aEach control group initially consisted of 240 animals.
bEach treatment group initially consisted of 60 animals.
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Table 19. Summary dose-response formulae for the effects of
DEN and DMN.
Chemical/
site Sex 1 -p(d,t)a at t = 2 years
DEN/ Female 11.16 * d3 t7 1430 d3
esophagus
DEN/ Male 21.17 d3 t7 2170 d3
esophagus
DEN/liver Female 32.09- (d + 0.4)4 t7 4110- (d + 0.04)4
DEN/liver Male 18.70 (d + 0.04)4 t7 2390 (d + 0.04)4
DMN/liver Female 51.45 (d + 0.1)6 * t7 6570 (d + 0.1)6
DMN/liver Male 37.43 * (d + 0.1)6. t7 4790 (d + 0.1)6
'Approximate cumulative incidence from exposure to dose d, given
in mg/kg-body weight/day, after t years.
procedure (28,29) in 1965; this uses the probit formula,
with the parameters chosen conservatively. At the
time, this choice was considered conservative. Since
1975, it has been realized that the dose-response rela-
tionship could be linear at low doses. In 1977 the FDA
changed over to usingrepresentations ofdose-response
relationships which are linear at low doses (203-205),
and the same approach was adopted by the EPA (44).
Risk Comparisons. In some cases, being too con-
servative is also too expensive, or can lead to unac-
ceptable hazards in other ways. This is wellrecognized,
for example, in the Federal Insecticide, Fungicide and
Rodenticide Act (FIFRA). Toxic chemicals are often
deliberately introduced into the environment for good
and sufficientpurposesofeliminatinginsects, fung, and
rodents. According to FIFRA, the risk ofthe chemical
must be compared with the risk ofalternatives, which
might include the insects, fungi, orrodents themselves,
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and the cost must be considered also.
It may be argued (206) that all risks are considered
comparatively by everybody in their everyday deci-
sions. Such a view is not universally accepted, and is
certainly not currently incorporated in regulatory pol-
icy. However, in risk-risk comparisons it is necessary
to estimate risks on a comparable basis. It is not ap-
propriatetoestimateoneriskconservatively, whilepro-
ducing a best estimate for another. One particularly
common example ofsuch failure to calculate risks com-
parably is in comparison ofa chemical which is a known
carcinogen with another which has not been adequately
tested, with the latteroftenbeingassumed tohavezero
risk. In the cases where a comparison is mandated, or
even desirable, great care should be taken to ensure
that similarassumptions are made inboth cases, sothat
uncertainties tend to cancel in any comparison.
Conclusions
In this review we have shown that there are no data
and few reliable theories to tell us the shape of dose-
response relationships at doses corresponding to a life-
time risk of one in a million, a value which is sufficient
to interestregulatory agencies. There are some data on
humans at incidences corresponding to lifetime risks of
1% and above; the two largest animal bioassays pro-
vided data at lifetime risks ofa few tenths ofa percent.
Biological reasoning suggests the presence ofnonlin-
earities ofall sorts in dose-response relationships (e.g.,
some theories on promotion allow for threshold effects,
FEMALE
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FIGURE 36. Observed/expected ratio of lethal cancers of the esophagus in rats versus dose of diethylnitrosamine (197,198). (A)Male rats;
(B)female rats. Curve A: a polynomial formula fitted to all the dose groups; curve B: a polynomial formula fitted to the lowest eight dose
groups; curve C: a linear formula fitted to the lowest eight dose groups.
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FIGURE 37. Observed/expected ratio oflethal cancers ofthe liverin rats versus dose ofdiethylnitrosamine (197,198). (A) Male rats; (B) female
rats. Curve A: a polynomial formula fitted to all the dose groups; Curve B: a polynomial formula fitted to the lowest eight dose groups;
Curve C: a linear formula fitted to the lowest eight dose groups; Curve D: a linear formula fitted to the lowest four dose groups.
a pure initiator can have a linear dose-response rela-
tionship, saturation of a metabolic pathway or popula-
tion effects can lead to a superlinear relationship). Su-
perlinearities are usually attributed to only a few
phenomena that should be distinguishable by experi-
mentation. All known examples are high-dose effects,
and it is not clear whether superlinearities occur in the
unobservable low-dose range. The observed linear and
sublinear dose-response relationships can be explained
variously, with models of each explanation suggesting
substantially different estimates of risk at low doses.
Anassumptionoflinearityshouldthengiveareasonable
upper bound for low dose risk estimates, but this may
not be helpful if a threshold is strongly indicated and
control costs are relatively high.
Data from animal experiments are often used to in-
dicate the presence of nonlinearities in dose-response
relationships, and the precision ofsuch experiments can
be high enough to clearly delineate such nonlinearities.
However, there is no guarantee that the dose-response
relationship in humans will be similar to that found in
experimental animals. There may be species differ-
ences, and the interindividual variability in humans is
likely to be larger than that between inbred experi-
mental animals. Furthermore, humans are simultane-
ouslyexposed to more variable amounts ofotheragents
that can affect carcinogenesis than are experimental
animals kept in controlled conditions. Data from human
studies suggest that nonlinearities in dose-response re-
lationships are prevalent, but in many cases the appar-
ent nonlinearities may be artifacts due to limitations in
data collection and analysis. Many published data may
be misinterpreted by failure to take account of age ef-
fects and the effects ofdose timing. The usual effect of
such omissions has been to cause a dose-response re-
lationship to appear more sublinear.
The best data from a human study, that on cigarette
smokinghabits ofBritishphysicians, showssublinearity
(risk approximately quadratic in the number of ciga-
rettes smoked). The data on Austrian lung cancer vic-
tims' exposure to cigarette tar are also consistent with
this sublinearity. The data on radiation exposures are,
in general, better than that for other human carcino-
gens, thoughusuallynot precise enoughtoidentifynon-
linearities. High LET radiation is expected to give a
linear response at low doses and superlinearity ifdoses
are high enough, while for low LET radiation one an-
ticipates sublinearity at low doses. Observations on the
dose-response relationship for low LET radiation
(breast, thyroid, and leukemias from medical or X-ray
treatments or exposure to the atomic bomb) are all con-
sistent with linearity. The most recent reanalysis of
leukemia incidence in atomic bomb victims suggests a
slight upward curvature. For high LET radiation there
are indications of superlinearity and dose-rate depen-
dence at high doses (bone cancer in ankylosing spon-
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FIGURE 38. Observed/expected ratio oflethal cancers oftheliverinratsversus dose ofdimethylnitrosamine (197,198). (A)Malerats; (B)female
rats. Curve A:a polynomial formula fitted to all the dose groups; Curve B:a polynomial formula fitted to the lowest eight dose groups;
Curve C: a linear formula fitted to the lowest eight dose groups; Curve D: a linear formula fitted to the lowest six dose groups.
dylitis victims and dial painters exposed toradium), but
at low doses the relationship is equivocal, with some
evidence ofsublinearity inthe case ofunderground min-
ersexposed toradongas. Althoughtherehasbeen some
debate over whether effects have been superlinear at
low doses, it seems unlikely that these datawill support
this hypothesis, but it will require further follow-up to
be sure. The effects measured in geographical areas
with high levels ofbackground high LET radiation also
do not appear to be consistent with an assumption of
superlinearity, while the data ofhigh-dose occupational
exposures are not precise enough to determine whether
they are consistent with a sublinearity assumption. One
major difficulty in drawing any conclusion is that the
result depends on how much synergism one assumes
between cigarette smoke and radon gas. In summary,
reliable high dose data from human studies contains
examples ofsuperlinearity (radium injections and bone
cancer), linearity (various radiation exposures), and
sublinearity (smoking).
The variety of shapes of dose-response curves ob-
served for humans is also seen for animals. Statistical
analysis of a large number of small experiments indi-
cates the presence of both sublinear and superlinear
curves at high doses. In relatively small experiments
onaflatoxin B1, onefinds someexperimentssignificantly
nonlinearatlowdoses, otherslinear. Thedose-response
curve for saccharin has been studied in several ways.
All bioassayresults appear to be sublinear, ifthey were
sensitive enough to detect any effect. Several biological
mechanisms suggested for the action of saccharin have
been tested in a variety of animal experiments. There
is some evidence for each mechanism, suggesting that
one should be cautious in accepting any one ofthem as
the correct mechanism.
Radiationcarcinogenesisinrodentsappearstobecon-
sistent with theoreticalideas: upward curvature forlow
LET radiation, superlinearity at high doses for high
LET radiation. The well-known case of superlinearity
for Maltoni's vinyl chloride experiments has been ex-
plained by a pharmacokinetic mechanism,. Taking into
account pharmacokinetics by using the. effective dose
givesadose-responsecurvethatappears sublinear. The
large set ofsmallexperiments onbenzo[a]pyrene shows
it to be more potent ifgiven at a high dose rate, and a
single, larger experiment is consistent with this inter-
pretation.
The largest bioassay reported to date is that on 2-
AAF fed to BALB/c mice. The dose-response relation-
ship found for liver cancers in this experiment is con-
sistent with a nonlinear pharmacokinetic model, with a
multistage model in which an early stage is affected, or
with a multistage model in which two stages are af-
fected. The dose-response curve for bladder cancer, a
much rarer tumor, was strongly sublinear.
Finally, the large experiments on N-diethyl- and N-
dimethylnitrosamine show substantial nonlinearities
overthe entire range ofdosestested. Ofspecial interest
were the comparisons of the low dose responses with
those athigherdosesinboththerareesophagealtumors
301302 ZEISE, WILSON, AND CROUCH
and the more common liver tumors. The more common
tumors might be expected to give a much more linear
dose-response curve in the low dose regime, as dis-
cussed in "Dose Response Formulae." The dose-re-
sponse curve for liver tumors actually appeared to be
as nonlinear at low dose as that for esophageal tumors,
at least in female rats.
Formany cases where nonlinearity is found in animal
bioassy data, auxiliary data (e.g., on mutagenesis and
pharmacokinetics) should be capable of providing ad-
ditional information on the cancer dose-response rela-
tionship outside the range observable in animal carcin-
ogenesis bioassays. However, careful study of those
chemicals with a well-characterized dose-response re-
lationship for carcinogenesis, including accumulation of
manymore dataonpharmacokinetics and celldynamics,
together with careful mathematical modeling, is re-
quired to distinguish between plausible biological ex-
planations ofsuch data. Currently, such additional data
are too few and the explanations too inadequately ver-
ified for them to be used for regulatory purposes.
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